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6ABSTRACT
Cigarette smoking is the most widespread form of drug abuse due to the addictive
properties of nicotine present in tobacco. Via binding to specific receptors, known as nicotinic
acetylcholine receptors (nAChRs), nicotine activates the mesolimbic dopamine (DA) system,
which is hypothesised to be the final common pathway shared by rewarding stimuli in the brain.
In addition to the mesolimbic dopaminergic system, nicotine also targets the nigrostriatal DA
system along with several other neurotransmitter systems in the brain, and it is the convergence
of these different stimuli that most probably contributes to the pharmacological effects of
cigarette smoking.
The purpose of these studies was to characterise the different nAChR subtypes that
mediate the effects of nicotine on mesolimbic and nigrostriatal dopaminergic neurotransmission
as well as on the postsynaptic expression of Fos protein in rat brain in vivo. The
pharmacological tools used were mecamylamine, dihydro--erythroidine (DHE) and
methyllycaconitine (MLA), that selectively block different nAChR subpopulations, and the
nAChR agonists epibatidine and nicotine. Furthermore, the effect of ambient temperature on
nicotine-DA interactions was investigated. Also, the nicotine-mediated responses were studied
in rats during continuous exposure to nicotine and after its withdrawal to clarify the degree to
which nAChRs are desensitised/inactivated during chronic exposure to the drug.
Nicotine’s effects on DA release were found to depend on ambient temperature in the
caudate-putamen, but not in the nucleus accumbens. Thus, it seems that the functioning of
nigrostriatal, but not that of the mesolimbic DA neurons is altered at elevated ambient
temperature (30-33C vs. 20-23C). The enhancement of nicotine-induced DA release in the
caudate-putamen at the high temperature was found to be antagonised by various nAChR
antagonists. Furthermore, it is probable that different nAChR subpopulations mediate nicotine’s
effects on DA release and metabolism. Additionally, there seems to be differences in the
agonistic effects of nicotine and epibatidine on nAChRs controlling dopaminergic functions in
the brain. Within the mesolimbic system, epibatidine-induced DA release is more prone to
desensitisation than nicotine-induced DA release. In contrast, within the nigrostriatal system,
epibatidine’s stimulatory effects on DA release are less easily desensitised than nicotine’s
effects.
During constant presence of nicotine, the majority of nAChRs controlling brain DA
functions were found to be persistently inactivated. However, a subpopulation of nAChRs is
resistant to desensitisation as reflected by the increased limbic DA turnover during constant
nicotine infusion, and by the ability of acute nicotine injection to further elevate limbic DA
turnover during chronic nicotine infusion. The changes in dopaminergic functions were parallel
to changes in Fos protein expression in dopaminergic brain areas.
The increases of Fos protein expression were found to be mediated in most brain areas by
DHE -sensitive nAChRs such as 42. However, mecamylamine-sensitive but DHE-
insensitive subtypes as well as MLA-sensitive subtypes, e.g. 7-containing nAChRs, are also
involved in some brain regions studied. In addition, systemic nAChR blockade by
mecamylamine, DHE or MLA in itself increases brain Fos expression most probably by
inhibiting transmitter release and interrupting polysynaptic feedback pathways. The findings
that antagonists are able to reproduce some of nicotine's effects at the level of immediate early
genes, suggest that some of nicotine's effects traditionally attributed to receptor activation may
in fact be caused by desensitisation of nAChRs.
Brain nAChRs are interesting therapeutic targets considering attempts to treat severe
neurological and psychiatric diseases, e.g. Alzheimer’s and Parkinson’s diseases, pain and
schizophrenia. A major drawback limiting the clinical use of nAChR agonists has been the
addictive and toxic effects of the lead compound nicotine. The present findings that there are
differences in nAChR desensitisation in response to different agonists may prove an important
clue in the search for new therapeutic compounds with less abuse potential.
7ABBREVIATIONS
ACh acetylcholine
ANOVA analysis of variance
AP-1 activator protein 1
BgT -bungarotoxin
CaM calmodulin
cAMP adenosine 3’, 5’-cyclic monophosphate
CNS central nervous system
COMT catechol-O-methyltransferase
CPu caudate-putamen
CRE calcium/cAMP responsive element
CREB calcium/cAMP responsive element binding protein
DA dopamine
DHE dihydro--erythroidine
DOPA 3,4-dihydroxyphenylalanine
DOPAC 3,4-dihydroxyphenylacetic acid
Fos IS Fos-like immunostaining
GABA -aminobutyric acid
GC-MS gas chromatography-mass spectrometry
5-HT 5-hydroxytryptamine (serotonin)
HVA homovanillic acid
IEG immediate early gene
IPN interpeduncular nucleus
LDTg laterodorsal tegmental nucleus
MAO monoamineoxidase
MLA methyllycaconitine
mPFC medial prefrontal cortex
mRNA messenger ribonucleic acid
3-MT 3-methoxytyramine
8NAcc nucleus accumbens
nAChR nicotinic acetylcholine receptor
NGS normal goat serum
NMDA N-methyl-D-aspartate
NRS normal rabbit serum
PBS phosphate-buffered saline
PKA protein kinase A
PPTg pedunculopontine tegmental nucleus
PVN paraventricular nucleus of the hypothalamus
SEM standard error of the mean
SN substantia nigra
SNc substantia nigra pars compacta
SON supraoptic nucleus of the hypothalamus
VTA ventral tegmental area
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1. INTRODUCTION
At the beginning of the 1990’s there was still some debate as to whether cigarette
smoking is a form of drug addiction or simply a social habit. However, it had
become evident that cigarette smoking reduces life expectancy due to the harmful
effects of tar, carbon monoxide, and irritants, such as NO
2
 and formaldehyde.
Smoking increases the risk of cancer, ischaemic heart disease and chronic
bronchitis, and deaths from tobacco use greatly outnumber deaths from other
abused drugs (Peto 1994). Today, it is widely recognised that smokers smoke
because they have become addicted to the pharmacological effects of nicotine
present in tobacco. Evidence exists that the mesolimbic dopamine (DA) system is
critically involved in the sensation of reward experienced by cigarette smokers,
including elevation of mood, enhancement of cognition and decrease of appetite
(Corrigall et al., 1994; see Benowitz 1996 for a review). In this respect the
reinforcing actions of nicotine are very similar to those of other drugs of abuse,
e.g. cocaine and amphetamine (Wise and Bozarth 1987; Robinson and Berridge
1993). Animals perform various tasks to obtain nicotine as reward, learn quickly
to self-administer it, and a physical withdrawal syndrome occurs in both
experimental animals and humans accustomed to regular nicotine intake.
However, the behavioural actions of nicotine are more subtle than those of
cocaine, amphetamine or opioids, in all probability due to the ability of nicotine
to self-regulate its stimulatory effects by closing down (desensitising) the ion
channels that mediate its effects after initial activation. Indeed, the major feature
distinguishing nicotine from most other abused drugs is that socially disruptive
manifestations, such as intoxication, violence or impaired performance do not
usually occur.
The actions of nicotine are initiated by its binding to nicotinic acetylcholine
receptors (nAChRs), which are multimeric ligand-gated ion channels encoded by
a large gene family. Recent advances in the understanding of the structure and
11
distribution of nAChRs in the brain open the door for studying the role these
receptors play in a variety of brain functions in vivo. The conclusion that a major
function of nAChRs is to modulate the release of several important
neurotransmitters has generated interest in nAChRs as putative therapeutic targets
for diverse neurological and psychiatric diseases, e.g. Alzheimer’s and
Parkinson’s diseases and schizophrenia (Wonnacott 1997; Lloyd and Williams
2000). Thus, something good could come from an addictive drug after all.
The purpose of these studies was to characterise the role of different nAChR
subtypes in the regulation of cerebral dopaminergic transmission and Fos protein
expression in vivo. To enable this to be done various nAChR antagonists were
employed that selectively block different nAChR subpopulations, and also by
comparing the effects of the nAChR agonists epibatidine and nicotine in rats.
Furthermore, the effect of ambient temperature on nicotine-DA interactions as
well as that of continuous nicotine exposure on dopaminergic transmission and
Fos protein expression were investigated to clarify the degree to which nAChRs
are desensitised/inactivated under these conditions. The principal research
methods used were in vivo microdialysis in freely moving rats and
immunohistochemical mapping of Fos protein. Microdialysis studies were
conducted in dopaminergic terminal areas. Due to the higher anatomical
resolution of the Fos immunohistochemical method, it was possible to study
several additional regions that are thought to mediate nicotine’s effects, e.g.
hypothalamus and visual system, for comparison.
All studies described in this thesis were carried out in vivo. Therefore, the
functional refractoriness of the responses studied is considered to reflect the
desensitisation of nAChRs, which are the primary mediators of nicotine’s actions
at the cellular level. However, it is to be noted that the effects of nicotine on
dopaminergic neurons involve also adaptive changes of neuronal function, not
necessarily related to initial activation of nAChRs.
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2. REVIEW OF THE LITERATURE
2.1. Nicotinic acetylcholine receptors in the CNS
2.1.1. Structure and classification
Nicotinic acetylcholine receptors (nAChRs) belong to the family of ligand gated
ion channels and show close sequence similarity to other receptor channels within
this group, namely those activated by glycine, -aminobutyric acid (GABA), and
5-hydroxytryptamine (5-HT). They have a pentameric cylindrical structure
organised around a central channel through which cations (Na
+
, K
+
, Ca
++
) pass
(Cooper et al., 1991). Different receptor subtypes are found at the neuromuscular
junction and in autonomic ganglia, brain and spinal cord. Brain nAChRs are
traditionally considered as “neuronal nAChRs”, but according to the recent
recommendation on nAChR classification (Lukas et al., 1999), this division is no
longer valid. Recent studies have shown that the subunits comprising nAChRs
that are present in neurons are also found in sensory organs as well as in some
non-neuronal cells (Elgoyhen et al., 1994; Wessler et al., 1998).
The most well characterised nAChRs are those present at the neuromuscular
junction, being composed of 1, 1,  and (adult)/(fetal) subunits (reviewed by
Karlin and Akabas 1995). A different situation exists in the brain, where nAChRs
are formed by / subunit pairs or by  subunits alone. In the mammalian brain
there are at least six  (2, 3, 4, 5, 6, 7) and three  (2, 3, 4) subunits
encoded by distinct genes similar in sequence to the genes encoding muscle
nAChR subunits (Boulter et al., 1986; reviewed by McGehee and Role 1995).
The  subunits, 2, 3 and 4, form functional channels when expressed with
either 2 or 4 in Xenopus oocytes (Deneris et al., 1989; Heinemann et al., 1991;
Papke 1993). In contrast, the expression of 5 with any single  subunit or 3
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with any of the  subunits does not produce functional receptors. Also 6 seems
to form combinations preferentially with other / combinations (Gerzanich et
al., 1997; Fucile et al., 1998). The 7 subunits are capable of forming homomeric
receptors (Couturier et al., 1990; Cuevas and Berg 1998). The predominant
nAChR subtype in the brain is a combination of 4 and 2 subunits with a
stoichiometry of (4)
2
(2)
3
, but evidence for the presence of heteromeric
nAChRs comprised of three or four different subunits is accruing (Vernallis et al.,
1993; Conroy and Berg 1995; Ramirez-Latorre et al., 1996; Klink et al., 2001).
The second most abundant type is probably homomeric 7 nAChR (Drisdel and
Green 2000), but some evidence exists that 7 may form heteromeric receptors as
well (Girod et al., 1999).
14
Cell
membrane
Figure 2-1. Structural and functional states of nicotinic acetylcholine receptors
(nAChRs). a. Pentameric structure of nAChRs at the neuromuscular junction. Nicotine
binding sites are located at the interface of an -subunit and a non- -subunit. On the
right is a schematic presentation of one of the five subunits spanning the plasma
membrane. The transmembrane structure is similar to brain nAChR subunits. b. The
different functional states of nAChRs. Transitions from one state to another are
interconvertible. B = resting, A = active, D = desensitised, I = permanently inactivated
state. Different chemical substances bind to different sites at nAChRs, and prefer
different functional states. CB = competitive blockers, NCB = non-competitive
blockers, ACh = acetylcholine (endogenous agonist) and nicotine binding site. c.
Putative organisations of brain nAChRs. Adapted from Léna and Changeux (1998) with
permission from Elsevier Science.
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2.1.2. Distribution of nAChRs
Nearly every region of the CNS receives cholinergic input from either of the two
major clusters of cholinergic nuclei, the basal forebrain complex and the
pontomesencephalic system (Descarries et al., 1997). The diffuse nature of these
projections largely explains the wide distribution of nAChRs, serving as targets
for the endogenous agonist of cholinergic nerves, acetylcholine (see Sargent 2000
for a detailed review). In the brain, nAChRs are located in different parts of
neurons and have been subdivided into “somatodendritic”, “preterminal” and
“presynaptic” receptors (Rapier et al., 1988; 1990; Grady et al., 1992; Marshall et
al., 1996; Wonnacott 1997). There is a large body of evidence that nAChRs are
present in many types of neurons, including the cholinergic ones, in the brain
(Wonnacott 1997; Sorenson et al., 1998). It is also commonly observed that
individual neurons express more than one nAChR channel type. Therefore, it is
not possible to predict nAChR compositions based solely on the set of genes
expressed by a single neuron. The 2 subunit mRNA and protein are most widely
expressed and their distribution is generally similar to pattern of binding seen
with 3Hnicotine (Clarke et al., 1985; Hill et al., 1993). The distribution of 4
mRNA is less widespread than that of 2 mRNA, but these two subunits
comprise at least 90% of brain high affinity nicotine binding sites (Wada et al.,
1989; Flores et al., 1992). The mRNAs encoding 4 and 7 are found in equal
amounts. The distribution of 7 mRNA correlates with the binding of 125I--
bungarotoxin (-BgT) with the distribution being distinct from that seen with
3Hnicotine.
According to in situ hybridisation studies, areas expressing the strongest signal
for 4 and 2 include layers V-VI of cerebral cortex, medial habenula, thalamus,
mesencephalic dopaminergic nuclei and area postrema (Léna and Changeux
1998). The highest intensity signals for 7 are found in olfactory bulb, layers V-
VI of cerebral cortex, hippocampus, supraoptic nucleus of the hypothalamus and
16
vestibular nuclei. In contrast, the distribution of 3 and 5 is much more limited,
and 2, 6, 3 and 4 are only present in a few brain structures. Interestingly,
mRNA coding for the 6 subunit is selectively concentrated in dopaminergic
nuclei of the midbrain suggesting a role for 6 subunit in mediating nicotine’s
locomotor activating and rewarding effects (Le Novere et al., 1996).
2.1.3. Functional properties of nAChRs
Functional properties of nAChR subunit combinations are determined largely by
(1) their permeability to Ca
++
 and (2) their desensitisation properties (Cachelin
and Jaggi 1991; Gross et al., 1991; Vernino et al., 1992). Generally brain
nAChRs have a higher relative permeability to Ca
++
 than those at the
neuromuscular junction, with the most extreme example being that the
homomeric 7 receptor has a relative permeability to Ca++ even higher than that
of NMDA type of glutamate receptor (see figure 2-2. for accurate ratios). The 7
subtype of nAChRs also displays the most rapid desensitisation kinetics. Another
property of nAChR is that all types expressed in neurons exhibit inward
rectification, that is, they conduct inward currents at negative potentials but at
positive membrane potentials current does not flow through them (Haghighi and
Cooper 1998; 2000). Both  and  subunits confer distinctive functional
properties to the receptors they form (Luetje and Patrick 1991; Gerzanich et al.,
1998; Parker et al., 1998).
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AChR Profile
Associated
Properties
22 32 42 425 34 7
P
Ca
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Figure 2-2. Desensitisation properties of different nAChR subunit combinations
expressed in Xenopus oocytes. The relative Ca
++
/Na
+
 permeability (P
Ca
/P
Na
) of 7
nAChRs is higher than that of NMDA-receptors and they provide a major route of Ca
++
entry at rest or at hyperpolarised membrane potentials when NMDA-receptors or
voltage-gated Ca
++
 channels are silent (Rogers and Dani 1995). 
0 
= time constant of the
open state;  = conductance. Adapted from Role and Berg (1996) with permission.
Historically, the phenomenon of nAChR desensitisation was first described in
muscle by Katz and Thesleff (1957). Desensitisation is an intrinsic property of
the protein complex comprising a particular nAChR that occurs also in
reconstituted membranes (Fong and McNamee 1986). When subjected to
prolonged exposure to agonists, nAChRs expressed in neurons also undergo a
conformational change resulting in an inactive receptor that does not allow for
the passage of ions (see figure 2-1.). Desensitisation is a readily reversible
phenomenon and can occur both at activating and subactivating agonist
concentrations (Grady et al., 1994; Fenster et al., 1997; Lu et al., 1999). A
distinct phenomenon from desensitisation is permanent inactivation of nAChRs
with a time course of hours rather than seconds to minutes as has been described
for desensitisation (Aoshima 1984; Rowell and Duggan 1998; Fenster et al.,
1999a). A relatively short exposure,  5 min, to relatively small concentrations of
nicotine can produce long-lasting nAChR inactivation in rat striatal
synaptosomes, with the subunit composition of nAChRs possibly determining the
degree to which the receptors are desensitised (Fenster et al., 1997; Rowell and
Duggan 1998). Desensitisation and persistent inactivation of nAChRs are the

0

4 ms
20 pS
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processes that most probably contribute to the behavioural changes in humans
who are exposed to nicotine through the use of tobacco products. Chronic
exposure to a level of nicotine found in smokers (low nanomolar) resulted in
inactivation of 42- and 7-containing nAChRs, but inhibited 3 containing
receptors to a lesser extent (Olale et al., 1997; Alkondon et al., 2000). However,
at present there is no consensus to what degree nicotine’s effects are due to
inhibition rather than activation of nAChR signalling.
Continuous administration of nicotine results in increases in numbers
(upregulation) of nAChRs in both laboratory animals and chronic smokers
(Marks et al., 1983; Rowell and Li 1997; Court et al., 1998). Currently, this
phenomenon is not well understood. The mechanism behind upregulation has
been hypothesised to be due to decreased degradation of nAChRs (Peng et al.,
1994). Receptor upregulation has been proposed to reflect receptor
desensitisation, which may underlie functional tolerance to nicotine’s effects.
Accordingly, the half-maximal nicotine concentration necessary to produce
desensitisation was the same as that needed to induce up-regulation (Fenster et
al., 1999b). Furthermore, up-regulation has also been found to be initiated by the
nAChR antagonist mecamylamine (Peng et al., 1994). However, upregulation
does not always reflect desensitisation, since some up-regulated nAChRs are still
functional (Wang et al. 1998). The areas and alterations of nAChR subunits
critical for functional inactivation or upregulation have not yet been determined
in detail. A variety of factors may be involved including passage of calcium ions
and membrane lipid composition (Fenster et al., 1999a; Baenziger et al., 2000).
Covalent modifications of receptor structure, such as phosphorylation and
dephosphorylation, may also play a role (Huganir et al., 1986; Fenster et al.,
1999a).
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2.1.4. Physiological role of nAChRs
Physiological activation of nAChRs is dependent on signals derived from
cholinergic cells. Recent studies suggest that cholinergic transmission in many
parts of the brain involves diffusion of ACh in the extracellular space i.e. volume
transmission (Descarries et al., 1997). Structural evidence that only 7-14% of
ACh release sites (varicosities) make synaptic contacts strongly supports this
view (Descarries 1998). The functional significance of nAChR subtype diversity
in the brain is still a matter of considerable debate. Particular nAChRs do not
seem to be limited to particular presynaptic or postsynaptic functional roles.
Direct evidence for a role of brain nAChRs in mediating synaptic transmission is
scarce (see however Frazier et al., 1998) but suggest a modulatory role in
transmitter release. Indeed, at presynaptic sites, nAChRs modulate transmitter
release at many kinds of CNS synapses including adrenergic, cholinergic,
dopaminergic, GABAergic, glutamatergic and serotonergic nerve terminals
(Rowell and Winkler 1984; Rapier et al., 1988; 1990; Grady et al., 1992; Léna et
al., 1993; El-Bizri and Clarke 1994; McGehee et al., 1995; Clarke and Reuben
1996; Reuben and Clarke 2000; reviewed by Wonnacott 1997). Their activation
results in Na
+
 and Ca
++
 influx and consequent depolarisation of the nerve
terminal, which in turn activates voltage-gated Ca
++
 channels. On the other hand,
high Ca
++
 permeability in itself may lead to a sufficient increase in intracellular
Ca
++
 to activate exocytosis independently of voltage-gated Ca
++
 channels.
Brain nAChRs have been implicated in neural development, neuroprotection (via
Ca
++
 entry), mood, learning and memory and various disease states including
schizophrenia and Alzheimer’s and Parkinson’s diseases (for reviews see Role
and Berg 1996; Levin and Simon 1998; Adler et al., 1998; Belluardo et al., 2000).
The generation of knock-out mice lacking specific nAChR subunits has given
new information for their physiological importance (reviewed by Cordero-
Erausquin 2000). Only the 3 subunit appears to be necessary for survival (Xu et
al., 1999a). This subunit forms a nAChR that mediates fast synaptic transmission
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in the autonomic nervous system. Mice lacking the 4, 7, 9, 2, or 3 subunits
survive to adulthood without any severe behavioural deficits (Picciotto et al.,
1995; Orr-Urtreger et al., 1997; Booker et al., 1999; Marubio et al., 1999; Ross et
al., 1999; Vetter et al., 1999). In contrast, simultaneous knock-out of 2 and 4
subunits is lethal (Xu et al., 1999b). However, the absence of a single nAChR
subunit can be compensated for during development, and future studies using
inducible genetic modifications are needed for a more detailed characterisation of
nAChR function in the CNS.
2.1.5. Agonists and antagonists of nAChRs
In addition to nicotine and ACh, numerous other substances have been
discovered that either activate or inhibit nAChRs, and these compounds have
provided valuable pharmacological tools for understanding the function and
pharmacology of nAChRs. Detailed reviews on the various agonists and
antagonists can be found elsewere (Holladay et al., 1997; Lloyd and Williams
2000), and thus only agents used in the present experiments are described here
with emphasis on their in vivo effects.
Dihydro--erythroidine (DHE) is a plant alkaloid derived from the seeds of
Erythina americana. Already Lehman (1937) described the curare-like effect of
Erythina extracts on voluntary musculature. DHE is a tertiary amine that can
penetrate the blood-brain barrier (Decker et al., 1995). In addition to its effects on
muscle end-plates, DHE binds to heteromeric brain nAChR subtypes (Williams
and Robinson 1984). Various nAChR subtypes expressed in oocytes differ greatly
in their sensitivity to DHE-induced blockade of ACh-evoked currents (Harvey
et al., 1996). According to Harvey and co-workers (1996), the 34 subtype is
resistant to DHE, with 10 - 120-fold difference in sensitivity compared to other
heteromeric subunit combinations (22, 24, 32, 42, 44).
Furthermore, DHE displaces 125I-BgT binding from the putative 7 nAChRs
in rat brain only at very high (millimolar) concentrations (Decker et al., 1995). In
21
contrast to this observation, DHE is a potent inhibitor of 3Hnicotine binding.
Tritiated DHE also labels sites that co-localise with high affinity nicotine
binding sites composed of 42 nAChRs (Williams and Robinson 1984; Flores
et al., 1992). DHE is also an effective antagonist that has an effect on a wide
range of nicotine-induced behaviours (Corrigall et al., 1994; Stolerman et al.,
1997; Shoaib et al., 2000) which emphasises the central role of DHE-sensitive
(mainly 42) receptors in mediating nicotine’s effects.
Epibatidine is an extremely toxic compound originally isolated from the skin of
an Ecuadorian poison frog, Epipedobates tricolor (Spande et al., 1992). This
natural alkaloid is an exceptionally potent competitive nAChR agonist, and binds
to nAChRs with picomolar (heteromeric nAChRs) or low nanomolar (7
nAChRs) affinity (Spande et al., 1992; Badio and Daly 1994; Lembeck 1999).
The use of epibatidine as a radioligand has deepened the picture of nAChRs in
the brain. Specifically, epibatidine binds not only to 42- containing nAChRs,
that are also recognised by nicotine and cytisine, but also to 3- and 7
containing nAChRs (Perry and Kellar 1995; Marks et al., 1998). Its potent
analgesic activity has generated considerable interest in developing structurally
related compounds with improved safety profiles for use in pain management.
Additionally, in vitro, epibatidine has been reported to be 150-fold more potent in
stimulating DA release from rat striatal slices than (-)-nicotine (Sullivan et al.,
1994). However, epibatidine appears not to have reinforcing effects, as it is not
readily self-administered by mice (Rasmussen and Swedberg 1998), and rats
sensitised to the locomotor-stimulating effects of nicotine do not cross-sensitise
to epibatidine (Reuben et al., 2000).
Mecamylamine. Initial evidence for the existence of nAChRs in the brain was
based upon the fact that nicotine’s behavioural effects were antagonised by
ganglionic antagonists that penetrate the CNS, such as mecamylamine (Hall
1972; Mansner and Mattila 1975; reviewed by Martin et al., 1989). The nature of
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mecamylamine’s antagonism has not been defined clearly, as unlike DHE it
does not compete effectively for 3Hnicotine or 3Hacetylcholine binding to
brain tissue in vitro (Marks et al., 1986; Scimeca and Martin 1988). Instead, it is
believed to block the ion channel of the nAChR (Banerjee et al., 1990; Martin et
al., 1990). No large differences in the sensitivities between 42 and 7 nAChRs
to mecamylamine were found in oocytes (Chavez-Noriega et al., 1997). Nor does
mecamylamine seem to discriminate well between these subtypes (Meyer et al.,
1997; Damaj et al., 1999). NMDA receptors are also blocked by mecamylamine
(Snell and Johnson 1989) indicating that some of its effects may involve
inhibition of glutamatergic transmission.
Methyllycaconitine (MLA) is a natural alkaloid isolated from the seeds of
Delphinium brownii (Nambi-Aiyar et al., 1979). MLA inhibits 125I-BgT
binding to rat brain membranes with at least 100-fold selectivity for -BgT sites
compared to other nicotinic binding sites (Ward et al., 1990; Davies et al., 1999).
At low nanomolar concentrations, MLA produces a potent and reversible
blockade of 7, but not 32 or 42, responses in oocytes (Wonnacott et al.
1993). However, at micromolar concentrations, MLA has affinity for a number of
nicotinic sites, including 42 (Drasdo et al., 1992; Buisson et al., 1996). It has
been demonstrated that MLA can enter the brain following peripheral
administration (Turek et al., 1995). Studies with MLA have reported negative or
conflicting results of the role of 7 receptors in nicotine-mediated behaviours.
Neither the discriminative stimulus effect (Brioni et al., 1996) nor the tail flick
analgesia response (Rao et al., 1996) appears to involve the 7 subunit.
Furthermore, MLA has been shown to have no significant effect against nicotine-
induced improvement of attentional performance (Blondel et al., 2000; Grottick
and Higgins 2000). Administration of MLA into the VTA of rats treated
chronically with nicotine produced withdrawal signs, and in particular a
significant reduction of spontaneous motor activity (Nomikos et al., 1999).
Furthermore, MLA microinjected into the VTA antagonised the nicotine-induced
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reduction in intracranial self-stimulation threshold (Panagis et al., 2000a). In
contrast, Grottick et al. (2000) were unable to identify any involvement of 7
receptors in maintaining nicotine self-administration and hyperactivity after i.p.
injections of MLA. MLA induced blockade of nicotine-induced seizures has been
recently reported by Damaj et al. (1999) suggesting a role for 7 receptors.
2.2. Brain dopaminergic systems
2.2.1. Biosynthesis and metabolism of dopamine
Synthesis of dopamine (DA) and other catecholamines begins with the amino
acid tyrosine, which is taken up by nerve cells from the blood (reviewed by
Cooper et al., 1996; Elsworth and Roth 1997). DA synthesis itself takes place in
the cell body or in the synaptic terminals themselves (Björklund and Lindvall;
Nissbrandt et al., 1989 and references therein). The synthetic pathway then
converts tyrosine to 3,4-dihydroxyphenylalanine (DOPA); catalysed by tyrosine
hydroxylase) to DA (catalysed by DOPA decarboxylase). Hydroxylation of L-
tyrosine is the rate-limiting step in DA biosynthesis whereas the decarboxylation
of DOPA to DA is an extremely rapid process. Newly synthetised DA is
protected from intraneuronal degradation by uptake and storage into synaptic
vesicles (see Kelly 1993 for a review). Vesicular transporters function to
counteract the considerable leak of transmitter from stores into the cytoplasm.
However, on induction of depolarisation and Ca
2+
 influx, DA is released from the
vesicles by exocytosis. The main mechanism responsible for terminating the
interaction of DA with its receptors is active re-uptake into the presynaptic nerve
terminal by transporter molecules. DA is also removed from the extracellular
space by diffusion out of the synaptic cleft and by extraneuronal metabolism.
The major route for DA metabolism is oxidative deamination by monoamine
oxidase (MAO). MAO is the sole metabolising enzyme present in
catecholaminergic neurons, but it is also found in glial cells and extraneuronally
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(Silberstein et al., 1972; Agid et al., 1973; Elsworth and Roth 1997 and
references therein). Within the nerve terminal, DA is converted to 3,4-
dihydroxyphenylacetic acid (DOPAC) by sequential activation of MAO and
aldehyde dehydrogenase. Two isoenzymes of MAO, A and B, are found in all
mammalian species, but DA appears to be a substrate for both forms of the
enzyme (Yang and Neff 1974; O’Carroll et al., 1983). DOPAC is then
transported out of the nerve terminal (Miyamoto et al., 1991) and undergoes O-
methylation to homovanillic acid (HVA) by catechol-O-methyltransferase
(COMT). An alternative metabolism pathway is conversion of released DA by
COMT to methoxytyramine (3-MT; Dedek et al., 1979). COMT is confined to
glial cells and postsynaptic neurons (Karhunen et al., 1995; Männistö and
Kaakkola 1999), thus O-methylated metabolites provide markers of DA release.
In the rat brain, DOPAC is the major metabolite, but the rate of HVA formation
closely follows that of DOPAC (Westerink 1979). In humans, however, the major
brain metabolite is HVA (Cooper et al., 1996).
Figure 2-3. Main pathways of catabolism of dopamine in the brain. Enzymes involved
are monoamine oxidase (MAO), catechol-O-methyltransferase (COMT), and aldehyde
dehydrogenase (ALD-D). Adapted from Elsworth and Roth (1997) with permission.
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2.2.2. Anatomical foundations
Dopaminergic neuron systems are principally located in the upper midbrain and
hypothalamus. Their shape varies from neurons with very restricted projections to
neurons with extensive axonal arborisations with the long-length mesencephalic
DA system being the largest system in the brain. Dahlström and Fuxe (1964)
divided it into three cell groups: A8, A9 and A10. The ventromedial-most group
includes A10 neurons that are located in the ventral tegmental area (VTA). A9
neurons are located in the substantia nigra (SN) and A8 neurons in the retrorubral
area, which lies caudal and dorsal to the SN. Traditionally, this anatomical
division of DA cells is considered to reflect differences in their efferent
projections, with projections of A10 to the nucleus accumbens (NAcc) and other
limbic areas (tuberculum olfactorium, septum, amygdala and bed nucleus of stria
terminalis) comprising the mesolimbic DA system, and projections from A9 to
the neostriatum (principally caudate and putamen) comprising the nigrostriatal
DA system (Dahlström and Fuxe 1964; Anden et al., 1964; 1966; Ungerstedt
1971). In contrast to the subcortical mesolimbic system, the VTA neurons
projecting to the cortical areas (medial prefrontal, cingulate and entorhinal
cortices) are usually referred to as the mesocortical system (Lindvall et al., 1974).
Later on, Fallon and Moore (1978) found another level of complexity in the
topography of ascending dopamine projections based on the finding that A9 and
A10 neurons form a continuum, with both groups contributing to the nigrostriatal
and mesocorticolimbic systems. In the 1980’s, it was recognised that mesolimbic
structures such as the NAcc and amygdala have “striatal” components and that
striatal structures such as the caudate-putamen (CPu) have limbic components
(Fallon 1988). The striatum is the main input structure of the basal ganglia. It is
divided into the dorsal striatum, which includes most of the Cpu, and the ventral
striatum, which comprises the NAcc, the ventromedial parts of CPu and part of
olfactory tubercle. Like the rest of the striatum, NAcc is characterised by a
patch/matrix compartmentation with the compartments able to be distinguished
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on the basis of different distribution of neuropeptides, DA receptors, opiate
receptors, calcium-binding proteins, and differences in connectivity
(Groenewegen and Russchen 1984; Voorn et al., 1989; Graybiel 1990). The
NAcc has been further divided into a core region related to the CPu and a shell
region associated with the limbic system (Záborsky et al., 1985; Deutch and
Cameron 1992; Zahm and Brog 1992).
2.2.3. Functional implications
The dopaminergic innervation of the striatum and cerebral cortex plays a central
role in a variety of motor, cognitive and emotional functions. DA dysfunction is
associated with complex pathological conditions, such as Parkinson’s disease and
schizophrenia (reviewed by Graybiel et al., 1990; Elsworth and Roth 1997; Lewis
and Lieberman 2000). In the rat, the motor striatum comprises the lateral CPu and
the associative striatum comprises the medial CPu (Joel and Weiner 1994). In
rats, neurons projecting to the motor and associative striatum reside in distict
regions, while in primates they are arranged in interdigitating clusters (Joel and
Weiner 2000). The limbic, or ventral striatum, receives extensive input from
other limbic structures, such as the hippocampus and amygdala, as well as from
prefrontal areas subserving limbic and autonomic functions. DA within the NAcc
and its other limbic target sites is associated with motivational, behavioural or
mood states and reward (Berke and Hyman 2000). Addictive drugs, in addition to
natural rewards, stimulate dopaminergic neurotransmission preferentially in the
shell division of NAcc (Di Chiara 1999) and blockade of dopaminergic
neurotransmission in this region attenuates the rewarding effects of addictive
drugs, such as conditioned place preference or self-administration (reviewed by
Wise 1996). Prefrontal DA (mesocorticolimbic system) modulates working
memory function (Goldman-Rakic 1996).
According to traditional views, the nigrostriatal and mesolimbic systems are
functionally separate in the sense that the former system is implicated in the
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control of posture and movement and the latter system in the rewarding and
dependence-producing effects of abused drugs (Willner et al., 1991 and
references therein). DA levels in the NAcc are elevated during appetitive
behaviours including feeding, drinking and copulation (Radhakishun et al., 1988;
Damsma et al., 1992; Young et al., 1992). However, elevation in dorsal striatal
DA levels have also been observed during these behaviours, but on a smaller
magnitude than those observed within the NAcc. Similar results have been
derived from animal studies involving drugs of abuse (Di Chiara and Imperato
1988). In addition, both ventral and dorsal parts of the striatum are involved in
the control of different motor behaviours. Pharmacological stimulation of DA
transmission selectively in the NAcc increases locomotor activity, whereas
stereotyped motor behaviours are observed following selective activation of
dorsal striatal DA neurons (Kelly et al., 1975). Thus, the neuronal circuits
mediating reward and motor activation seem to overlap, and recent data from
electrophysiological and microdialysis studies suggest that elevations in DA
release within mesolimbic, mesocortical and nigrostriatal target sites coincide
with different stimuli, and modulate an overlapping category of behavioural
functions (reviewed by Horvitz 2000). Furthermore, midbrain DA neurons seem
to be activated by a large category of arousing events including novel and even
aversive events such as stressful stimuli (Abercrombie et al., 1989; Schultz
1998).
2.2.4. Cellular actions
Nearly every striatal neuron receives dopaminergic input (Andén et al., 1966;
Schultz 1998). The average distance between release sites is only 4 	m, and the
dynamics of DA reuptake allow for rapid diffusion to extrasynaptic receptors
(Gonon 1997; Berke and Hyman 2000). There are at least five DA receptor genes
coding for D
1
 (D
1
, D
5
) and D
2 
(D
2
, D
3
, D
4
) receptors, all of which are expressed
in the neostriatum and belong to the family of G protein coupled receptors.
Approximately 80% of striatal DA receptors are D
1
 receptors that activate
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adenylate cyclase and are localised mainly outside dopaminergic synapses (Caillé
et al., 1996; Schultz 1998). 30-40% of DA is released from synaptic sites and
with 60-70% released from extrasynaptic sites (Descarries et al., 1996; Zoli et al.,
1998). Midbrain DA neurons display firing patterns which include both single
spike activity and firing in bursts (Grace and Bunney 1984) with the amount of
DA released dependent on the rate and pattern of firing (Garris and Wightman
1994). Firing at high frequencies (20-100 ms), and especially burst firing, leads to
higher extracellular DA concentrations in the CPu and NAcc than firing at low
frequencies. This is due to the rapid saturation of the DA transporter, which is
responsible for the clearance of DA from the extracellular space (Chergui et al.,
1994). In contrast to the Cpu, in the NAcc, this effect occurs even when longer
impulse intervals are observed, due to lower efficiency of DA uptake (Marshall et
al., 1990). Recent studies have proven that the effect of DA on neuronal activity
in the NAcc is state-dependent (Calabresi et al., 1997; Hérnandez-López et al.,
1997). In the presence of cortical glutamatergic input, DA increases the impact of
this excitatory input, whereas in the absence of depolarising stimuli, DA inhibits
neuronal activity.
2.2.5. Dopamine and basal ganglia neural circuits
The dorsal and ventral striatum are components of complex neural circuits that
project from various cortical regions through the basal ganglia to the midbrain
and back to the cortex (Graybiel 1990; Gerfen 1992; Harlan and Garcia 1998).
The dorsal striatum receives glutamatergic input mainly from various cortical
areas while other regions such as the hippocampus and amygdala provide
glutamatergic input to the ventral striatum. More than 90% of striatal neurons are
medium-sized GABAergic cells that integrate information from cortical
glutamatergic and midbrain dopaminergic inputs. GABAergic spiny neurons
themselves project out of the striatum and back to the dopaminergic cell bodies in
the midbrain. The striatonigral pathway provides direct input to the substantia
nigra. Striatopallidal neurons provide input to the globus pallidus which in turn
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provides GABAergic inhibitory input to the substantia nigra and subthalamic
nucleus.
In addition to GABAergic projections, dendrites and cell bodies of DA neurons in
the midbrain receive extensive input from many parts of the CNS. Cholinergic
neurons in the laterodorsal tegmental nucleus (LDTg) regulate the activity of DA
neurons in the VTA whereas DA neurons in the substantia nigra pars compacta
(SNc) receive cholinergic input mainly from the pedunculopontine tegmental
nucleus (PPTg; Oakman et al., 1995; Blaha et al., 1996). Recently, data from
lesioning studies and blockade of the PPTg nAChRs by DHE indicated that the
cholinergic PPTg projection to midbrain plays a role in the maintenance of
nicotine self-administration (Lança et al., 2000a). Midbrain DA neurons receive
excitatory noradrenergic input from the locus coeruleus, whereas serotonergic
efferent neurons from the raphe nuclei inhibit the activity of DA neurons. The
DA neurons also receive excitatory glutamatergic input from the prefrontal
cortex, thalamus, subthalamic nucleus, PPTg, and LDTg (Fonnum et al., 1981;
Karreman and Moghaddam 1996; Harlan and Garcia 1998), and it has been
suggested that activation of presynaptic nAChRs located on these terminals
mediate at least part of the nicotine-induced stimulation of midbrain DA neurons
via increased glutamate release (Schilström et al., 1998; 2000a; Balfour et al.,
2000).
2.3. Effects of nicotine on dopamine-mediated behaviours
2.3.1. Anatomical foundations
Systemically administered nicotine may affect nAChRs concurrently at the site of
DA cell bodies in the VTA and SN and at the DA terminal areas e.g. in the NAcc
and CPu. A variety of nAChR subunits are densely distributed in the SN and
VTA, and the specific subunit compositions of the receptors formed have been
recently defined (Klink et al., 2001). Only minor differences were found in the
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mRNAs encoding various nAChR subunits within these two regions (Le Novere
et al., 1996; Sgard et al., 1999). Most DA neurons in the SN and VTA express
two nAChR subtypes putatively composed of465(2)
2
 or 45(2)
2
subunits. Furthermore, nearly half of the neurons in the DA nuclei express
homomeric 7 receptors. Additionally, non-dopaminergic neurons projecting to
midbrain dopaminergic nuclei such as GABAergic and glutamatergic projection
neurons express nAChR subunit mRNAs including those coding for the 4, 7,
2, and 3 subunits (Sgard et al., 1999). At the level of dopaminergic terminals,
the subunit compositions of nAChRs are not as well defined. Receptors
composed of 3, 4, and 2 subunits have been implicated in DA release from
striatal synaptosomal preparations (Kulak et al., 1997; Kaiser et al., 1998;
Sharples et al., 2000; Wonnacott et al., 2000). However, the 6 subunit is likely
to be involved and due to its close sequence similarity to 3 subunit, it may have
been recognised by 3-selective molecular tools (Le Novere et al., 1996).
Interestingly, immunogold electron microscopy has revealed that 7 nAChRs are
absent from dopaminergic terminals in the striatum, but are located at
neighbouring glutamatergic terminals (Wonnacott et al., 2000). On the other
hand, 2-containing nAChRs were absent from glutamate terminals.
Furthermore, although nAChRs are present in the cerebral cortex, they are not
located presynaptically on mesolimbocortical DA terminals but on interneurons,
according to electrophysiological and lesion studies (Schwarz et al., 1984; Vidal
etal., 1989; Porter et al., 1999) or alternatively, on terminal regions of cortical
projection neurons as discussed in chapter 2.2.5.
2.3.2. Cellular actions
Studies using experimental animals have shown that nicotine’s effect on midbrain
DA neurons depends largely on the dose, administration protocol (intermittent
injections vs. chronic infusion) and duration of treatment. At the first exposure,
nicotine stimulates the synthesis, metabolism and release of DA and the
functional activity of DA neurons in vitro and in vivo. Acute systemic
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administration of nicotine is known to increase the firing of midbrain DA neurons
(Lichtensteiger et al., 1976; 1982; Clarke et al., 1985; Grenhoff et al., 1986), and
DA neurons located in the VTA are most sensitive to nicotine’s effects (Mereu et
al., 1987). Furthermore, nicotine has been shown to stimulate DA release in vitro
in slices and synaptosomal preparations prepared of accumbal or striatal tissue
(Westfall et al., 1983; Rowell et al., 1987; Rapier et al., 1988; Dluzen and
Anderson 1998) as well as to elevate striatal DOPAC and homovanillic acid
HVA concentrations in rats and mice (Nose and Takemoto 1974; Haikala et al.,
1986; Brazell et al., 1990). DA metabolite measurements from tissue samples and
even more convincingly, in vivo microdialysis studies have demonstrated that
nicotine administered acutely preferentially stimulates DA release and
metabolism in the NAcc (especially the shell compartment) compared to its effect
in the dorsal striatum, where elevation of extracellular DA by nicotine was found
to occur only under certain conditions (elevated extracellular Ca
++
 or use of a DA
uptake blocker; Imperato et al., 1986; Grenhoff and Svensson 1988; Brazell et al.,
1990; Toth et al., 1992; Benwell and Balfour 1997, Nisell et al., 1997a).
Somatodendritic nAChRs seem to be of greater importance in regulating DA
release by systemic nicotine than those located presynaptically, as infusion of
mecamylamine into the VTA, but not into the NAcc antagonised nicotine-induced
DA release (Nisell et al., 1994). Recent studies have suggested that nicotine-
induced DA release is modulated by nAChRs located on glutamate terminals that
increase glutamate release. Glutamate in turn stimulates midbrain DA neurons by
increasing burst firing via NMDA receptors. Evidence exists that glutamate-DA
interactions take place in the VTA and that the nAChR subtype involved is 7
(Schilström et al., 1998; 2000a). Recently, however, intra-accumbal infusion of
the 7 nAChR antagonists MLA and -bungarotoxin were found to partially
inhibit DA release by i.v. nicotine, supporting a model in which 7-containing
nAChRs on striatal glutamate terminals modulate DA release from striatal DA
terminals (Fu et al., 2000; Kaiser and Wonnacott 2000). Increased DA utilisation
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by acute nicotine has been described also in the prefrontal cortex, but the nAChR
subtypes involved are presently not known (George et al., 1998).
Repetitive injections of nicotine given within a relatively short time window (5
days) results in sensitisation (enhancement) of nicotine-induced DA release in the
core component of the NAcc (Benwell and Balfour 1992; Cadoni and Di Chiara
2000). Development of sensitisation is believed to be dependent on
glucocorticoids, glutamatergic mechanisms, and most likely reduced function of
DA autoreceptors (Shoaib et al., 1994a; Johnson et al., 1995; Balfour et al.,
1998). In contrast, a reduced, or unchanged response in DA release is observed in
the shell compartment of NAcc, and the anatomical heterogeneity between the
core and shell is interpreted to explain earlier studies in which either an
unchanged or an enhanced response was found following repeated nicotine
injections in the NAcc (Damsma et al., 1989; Benwell and Balfour 1992; Nisell et
al., 1996; Cadoni and Di Chiara 2000). Sensitisation is also observed in the
mPFC, following a slightly longer nicotine treatment (12 days; Nisell et al.,
1996). When nicotine is administered acutely via a microdialysis probe directly
into the dorsal striatum, NAcc, or frontal cortex of nicotine-pretreated rats,
sensitisation is observed independently of pretreatment protocol (chronic infusion
vs. repeated injections), with the enhancement of DA release being most marked
in the dorsal striatum (Marshall et al., 1997).
No sensitisation of DA release was observed in the NAcc core after continuous
nicotine infusion for 14 days (Benwell et al., 1995). Instead, constant nicotine
infusion resulted in desensitisation and long-lasting inactivation of nAChRs
mediating nicotine’s effects on mesolimbic and nigrostriatal DA neurons.
Interestingly, in in vivo microdialysis studies, to desensitise the DA release
response in the dorsal striatum a higher nicotine infusion rate is required than in
the NAcc, where DA release desensitises at lower infusion rates (Benwell and
Balfour 1997). However, elevated extracellular levels of DA in the NAcc shell
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are found in rats chronically infused with nicotine for 9 days compared to saline-
infused rats (Carboni et al., 2000). Although desensitisation of nicotine-induced
DA release is likely to occur following prolonged exposure to nicotine
(Pidoplicko et al., 1997) the results of Carboni et al., (2000) suggest that some
responsiveness still remains. Indeed, evidence exists that certain nAChR subtypes
are resistant to desensitisation (see chapter 2.1.3.). Hypothetically, inhibition of
DA uptake mechanisms by nicotine could also explain elevated DA levels during
continuous infusion (Izenwasser et al., 1991).
2.3.3. Body temperature
DA has been implicated in thermoregulation in rats (Clark and Lipton 1985), and
its hypothermia-producing effects are mediated via activation of D
1
 and D
2/3
receptors (Salmi 1998). The major brain areas involved in the regulation of body
temperature are the preoptic area and the hypothalamus. The warm-sensitive
neurons within these areas are excited and the cold-sensitive neurons inhibited by
local application of DA in a slice preparation (Scott and Boulant 1984).
Dopaminergic neurons in the SN are also thermoresponsive, as electrical
stimulation of the SNc produced hypothermia at ambient temperatures below
22
C as well as hyperthermia in rats at 30
C (Lin et al., 1992). Moreover nicotine
affects thermoregulation, by inducing hypothermia in drug-naïve experimental
animals (Hall 1973; Horstmann 1984). Nicotine-DA interactions have been
demonstrated in body temperature regulation, and are probably explained, in part,
by the excitatory action of nicotine on SNc neurons. In mice, when the
hypothermic effect of nicotine is antagonised by elevating the ambient
temperature, the stimulating effects of nicotine on striatal DA metabolism are
enhanced and found at smaller nicotine doses (Haikala et al., 1986; Leikola-Pelho
et al., 1990). Indeed, in mice, repeated nicotine doses which induced profound
hypothermia also decreased striatal DA release as estimated from the effects on
DA metabolites (Haikala 1986).
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2.3.4. Motor behaviour
Nicotine either stimulates or depresses motor behaviour in rats depending on the
dose, administration protocol, duration of treatment and habituation to the
environment. For the most part, nicotine’s locomotor activating effects are most
likely to be mediated via activation of the mesolimbic and mesocortical DA
systems, as shown by the good correlation between locomotor sensitisation and
enhancement of DA release in the NAcc in response to repeated nicotine
injections (Di Chiara and Imperato 1988; Benwell and Balfour 1992). In naïve
rats, the initial effect observed is locomotor depression followed by stimulation
lasting approximately 1 hour (Morrison and Stevenson 1972; Stolerman et al.,
1973; Clarke and Kumar 1983; reviewed by Clarke 1990). Nicotine’s effects are
also modified by the basal activity of the subject, i.e. nicotine tends to stimulate
behaviour when baseline activity is low, while a decrease in behaviour is
observed when the baseline activity is high (reviewed by Rosecrans 1995). On the
basis of these observations, Rosecrans (1995) suggested that nicotine’s variable
effects may be related to its ability to either activate or desensitise distinct brain
nAChRs. The receptor subtypes involved in nicotine’s motor effects seem to be
heteromeric /-combinations, as mecamylamine but not the 7 antagonists
MLA or -bungarotoxin prevented sensitisation or a reduction in nicotine’s
motor effects (Grottick et al., 2000; Kempsill and Pratt 2000). Furthermore,
studies using mutant mice have revealed that the spontaneous activity of 4
nAChR knock-out mice is increased (Ross et al., 2000).
2.3.5. Reinforcement and withdrawal
Nicotine has been reported to produce conditioned place preference in rodents,
especially if the subject has a history of previous nicotine exposure similar to that
required to establish sensitisation of DA release in the NAcc (Shoaib et al.,
1994b). Nicotine self-administration has also been demonstrated in experimental
animals, but the conditions under which animals self-administer nicotine are
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more limited than for cocaine self-administration (Corrigall and Coen 1989;
Shoaib et al., 1997; Corrigall et al., 1999; 2000). Self-administered nicotine
appears to target the mesolimbic dopamine system through DHE-sensitive
nAChRs in the VTA (Corrigall et al., 1994). Pharmacological approaches using
nAChR antagonists (DHE or mecamylamine) and 7 selective antagonist MLA
have failed to demonstrate any involvement of 7 nAChRs in maintaining
nicotine self-administration (Watkins et al., 1999; Grottick et al., 2000). A
significant role for 2 containing nAChRs in nicotine self-administration has
been demonstrated using mutant mice lacking the 2-subunit (Epping-Jordan et
al., 1999). These mice learn to self-administer cocaine, but do not substitute for
nicotine as wild type mice do.
In the rat, withdrawal from continuous nicotine infusion involves abstinence
symptoms such as shakes, ptosis, teeth chatter, and changes in locomotor activity
(Malin et al., 1992; Hildebrand et al., 1997; Epping-Jordan et al., 1998). Both 7
and /-containing nAChRs appear to be involved in nicotine withdrawal
syndrome as reflected by the ability of different nAChR antagonists (DHE,
mecamylamine, MLA) to elevate brain stimulation thresholds (Huston-Lyons and
Kornetsky 1992; Epping-Jordan et al., 1998; Panagis et al., 2000a). A decrease in
DA output in the NAcc and central nucleus of amygdala is observed in
chronically nicotine-treated rats given nAChR antagonists (Hildebrand et al.,
1998; Nomikos et al., 1999; Panagis et al., 2000b). Again, nAChRs located in the
VTA are of some importance (Nomikos et al., 1999; Hildebrand and Svensson
2000). Decreased opioid transmission is also implicated in nicotine withdrawal
syndrome, although opiate antagonists do not reduce nicotine-induced dopamine
release (Malin et al., 1993; Carboni et al., 2000; Watkins et al., 2000). Nicotine
withdrawal syndrome is also thought to involve peripheral cholinergic
mechanisms (Hildebrand et al., 1997; Watkins et al., 2000).
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2.4. Effects of nicotine on intracellular signalling
Nicotine’s effects on gene expression are complex and involve activation of a
variety of secondary messenger systems and protein kinases (Greenberg et al.,
1986). The complexity derives from the fact that nicotine, acting on presynaptic
nAChRs, can alter the release of many different transmitter substances that in
turn activate various postsynaptic receptors and signalling systems. In the
following chapter, the most well-known of these are briefly reviewed, including
secondary messengers such as cyclic AMP (cAMP) and Ca
++
 that are critical
intracellular mediators of the effects of abused substances (Blendy and
Maldonado 1998). The effects of different drugs of abuse, e.g. nicotine and
cocaine, seem to involve common mechanisms at the level of gene transcription
(Merlo Pich et al., 1997; Harlan and Garcia 1998; Nestler 2001).
2.4.1. Second messenger systems
Activation of nAChRs results in an increase in intracellular Ca
++
. The route of
Ca
++
 influx may either be directly through nAChRs or indirectly by the
involvement of membrane depolarisation and subsequent activation of voltage-
gated Ca
++
 channels. A rise of intracellular Ca
++
 is often the first response to an
extracellular stimulus and can act as a trigger for activating numerous other
signalling pathways. Changes in intracellular Ca
++
 can influence events such as
neuronal survival, axon outgrowth and changes in synaptic strength (reviewed by
Berridge 1998). Ca
++
 also appears to be a central mediator of adaptive responses
(plasticity) in the nervous system (Ghosh and Greenberg 1995). In the case of
nicotine, Ca
++
 -mediated activation of protein kinase C has been implicated in the
regulation of nAChR desensitisation (Fenster et al., 1999a).
A critical transcription factor implicated in the development of drug dependence
is the cAMP response element binding protein (CREB; Montminy et al., 1990;
Shaywitz and Greenberg 1999; Nestler 2001). Nicotine can activate CREB-
signalling via DA release, which in turn stimulates the D
1
 class DA receptor
37
transduction pathway that involves activation of the cAMP-dependent protein
kinase (PKA) and phosphorylation of CREB (Berretta et al., 1992). Alternatively,
nicotine-induced increases of intracellular Ca
++
 can activate Ca
++
- calmodulin
(CaM)-dependent protein kinases that in turn can phosphorylate CREB directly or
indirectly, via activation of CaM-dependent adenylate cyclases (Ghosh and
Greenberg 1995).
2.4.2. Immediate early genes
Many of the protein products of inducible immediate early genes (IEGs) are
transcription factors which may regulate neuronal and non-neuronal gene
expression in the mammalian brain (Dragunow et al., 1989; Morgan et al., 1991).
Following cell stimulation, their expression is often rapid and transient owing to
the instability of these proteins and their respective mRNAs, but some gene
products accumulate during repeated stimulation, e.g. drug administration. The
prototypical IEG c-fos, a cellular homologue of viral oncogene v-fos of murine
osteosarcoma virus, was discovered in the early 1980’s, and its protein product
was named Fos (Curran et al., 1984). Since then, several IEG encoded proteins
have emerged including the Fos family (Fos, Fra1, Fra2, FosB and FosB) and
the Jun family (c-Jun, JunB, JunD), which forms heterodimeric complexes with
the Fos family members termed AP-1 (Curran and Franza 1988; reviewed by
Hughes and Dragunow 1995). Jun, but not Fos, family members also form
homodimers. The AP-1 forming proteins are important mediators of the effects of
abused drugs, e.g. amphetamine, cocaine, ethanol, morphine, nicotine and 9-
tetrahydrocannabinol (Chang et al., 1988; 1995; Graybiel et al., 1990; Kiba and
Jayaraman 1994; Miyamoto et al., 1996; reviewed by Harlan and Garcia 1998).
They act as transcription factors to regulate expression of as yet largely
unidentified target genes containing AP-1 binding sites. In the case of nicotine,
potential target genes include those encoding tyrosine hydroxylase, opioid
peptides, growth factors, and steroid receptors (Smith et al., 1991; Dhatt et al.,
1995; Johnson et al., 1995; Maggio et al., 1998).
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Figure 2-4. Nicotine is able to alter gene expression in brain cells by increasing the
release of various transmitter substances and by increased synthesis of growth factors.
By stimulating cell surface receptors, these environmental first messengers activate
various second messengers, e.g. Ca
++
, cAMP, and protein kinases. Changes in neuronal
gene expression are controlled by signal-regulated transcription factors, e.g. CREB and
immediate-early genes. CRE = calcium/cAMP responsive element, CREB =
calcium/cAMP responsive element binding protein, AP-1 = activator protein -1 binding
site. See text for details. Adapted from Hughes and Dragunow (1995) with permission.
The expression of c-fos in the CNS is low in the absence of depolarising stimuli
(Sagar et al., 1988). Both membrane depolarisation and calcium entry induce c-
fos transcription via phosphorylation of transcription factor CREB (Sheng et al.,
1990), and it has been demonstrated that nicotine’s effects on c-fos expression are
also mediated via increased phosphorylation of CREB (Hiremagalur and Sabban
1995). Immunohistochemical mapping of Fos protein has been extensively used
to study nicotine’s effects on postsynaptic cells and to characterise brain regions
activated in response to nicotine, although it cannot be considered a general
marker of neural activity in the CNS (Chaudhuri 1997). Studies on nicotine’s
effects on c-fos expression have used different administration protocols including
acute injections using naïve animals, i.v. infusions, repeated injections, chronic
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infusions via osmotic minipumps and self-administration protocols and have all
shown that nicotine activates c-fos expression on a widespread scale in the brain.
Acute systemic nicotine-injections increase c-fos mRNA or Fos-like
immunostaining (Fos IS) in the target areas of the midbrain DA neurones, areas
of the hypothalamus, areas related to optic system, various cortical areas
controlling motor activity, and pedunculopontine mesencephalic tegmentum of
rats (Ren and Sagar 1992; Matta et al., 1993; Sharp et al., 1993; Pang et al., 1993;
Kiba and Jayaraman 1994; Salminen et al., 1996; Lança et al., 2000b). The VTA
is centrally involved in the Fos-inducing effects of nicotine, since direct nicotine-
infusions into the VTA induce Fos-IS in the NAcc, and intra-VTA infusions of
nAChR antagonists, as well as NMDA antagonists, block this effect (Panagis et
al., 1996; Schilström et al., 2000b). Furthermore, the nAChR agonist epibatidine
induces a similar pattern of Fos IS as that observed for nicotine (Watanabe et al.,
1998).
Similarly to its effect on dopamine release and locomotor activity, repetitive
nicotine injections for several days result in enhancement of nicotine-induced Fos
responses (sensitisation) in the target areas of midbrain dopaminergic neurons,
specifically in the medial prefrontal, as well as in the parietal and cingulate
cortices and in the core and shell of NAcc (Nisell et al., 1997b; Mathieu-Kia et
al., 1998; Shim et al., 2001). Interestingly, nicotine self-administration studies
have shown that there are differences between brain areas expressing increased
levels of Fos IS depending on the administration protocol (Pagliusi et al., 1996;
Pich et al., 1997). The target areas of midbrain dopaminergic nuclei (medial
prefrontal and cingulate cortices, dorsal striatum, NAcc, septum) demonstrate
increased IEG expression in response to self-administration, whereas stress-
sensitive areas showing increased Fos expression in response to nicotine
injections (hypothalamic nuclei, locus coeruleus and amygdala) do not. Chronic
nicotine treatment with osmotic minipumps does not lead to increased CREB
phosphorylation or consequent activation of c-fos expression in the adrenal
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medulla, which probably reflects desensitisation of nAChRs during exposure to
the constant nicotine levels in the plasma (Hiremagular and Sabban 1995; see
also discussion). Mecamylamine-precipitated withdrawal from continuous
nicotine-infusion has been found to induce Fos IS in the central nucleus of
amygdala, but not in the medial prefrontal cortex, NAcc or dorsolateral striatum
(Panagis et al., 2000b) whereas opioid withdrawal clearly elevates the expression
of Fos-related antigens in the NAcc (Walters et al., 2000).
Mecamylamine, the non-competitive nAChR channel blocker, inhibits nicotine-
induced elevations of c-fos mRNA or Fos IS indicating that the Fos response is
related to nAChR activation and not due to unrelated responses to environmental
or other stimuli (Ren and Sagar 1992; Pang et al., 1993; Sharp et al., 1993; Kiba
and Jayaraman 1994; Schilström et al., 2000b). Blockade of nicotine-induced c-
fos expression in the dopaminergic terminal areas by D
1
 receptor antagonists and
NMDA receptor antagonists indicates that both dopaminergic and glutamatergic
mechanisms are involved in nicotine’s effects on IEG expression (Kiba and
Jayaraman 1994; Nisell et al., 1997b; Schilström et al., 2000b). The same
mechanisms also appear to regulate IEG expression by other drugs of abuse in the
dopaminergic regions (reviewed by Harlan and Garcia 1998).
2.5. Nicotine and Fos; Stimulus-transcription coupling uncertainty
When applying the IEG activity mapping approach, e.g. Fos protein
immunohistochemistry to in vivo studies, certain limitations must be taken into
account. Firstly, expression of IEGs is cell-type specific and only a subset of
neurons respond to different stimuli by increased Fos expression (Chaudhuri
1997). For example, the VTA and the SN do not express Fos in response to
nicotine in spite of the presence of nAChR subunit mRNAs in high amounts (Ren
and Sagar 1992; Léna and Changeux 1998). Secondly, nAChRs are located in
different parts of neurons and have been subdivided into “somatodendritic”,
“preterminal” and “presynaptic” receptors on the basis of their location
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(Wonnacott 1997). Therefore, nicotine-induced Fos IS, which is localised to the
cell nucleus, does not always correlate well with the distribution of nAChR
subunit mRNAs or the nicotine binding sites in the brain. Thus, stimulation or
blockade of nAChRs may alter the release of many different transmitters and via
altered transmitter release, induce Fos in postsynaptic cells that do not necessarily
express nAChRs. Thirdly, non-specific features of the experimental conditions
also contribute to the induction of Fos IS, the stress induced by animal handling
being one of the most important factors (Senba and Ueyama 1997). Therefore,
careful control of experimental conditions is essential for obtaining reliable
results.
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3. AIMS OF THE STUDY
Neuronal nAChRs are promising therapeutic targets in the search for novel drugs
to treat various neurological and psychiatric disorders, e.g. Alzheimer’s and
Parkinson’s diseases, pain and schizophrenia. However, nAChRs regulate brain
dopaminergic functions involved in the processing of rewarding stimuli, and the
high abuse potential of nAChR agonists (e.g. nicotine) is a major drawback
limiting their clinical use. The purpose of these studies was to characterise the
role that different nAChR subtypes play in the regulation of mesolimbic and
nigrostriatal dopaminergic transmission and Fos protein expression in the brain
and to describe how these markers change during chronic nicotine infusion and
its withdrawal. The specific aims were:
Nicotine-DA interactions have been demonstrated in the regulation of body
temperature. Therefore, investigation of whether elevation of the ambient
temperature affects nicotine-induced DA output and metabolism in the CPu and
NAcc was performed. After this was indeed found to be the case in the CPu,
further studies were conducted to investigate the involvement of different nAChR
subtypes in this phenomenon (I).
To compare the responses of the nigrostriatal and mesolimbic DA systems to
different nAChR agonists, namely nicotine and epibatidine (II).
To examine the effects of acute nicotine on DA metabolism and Fos protein
expression in the mesolimbic and nigrostriatal dopaminergic terminal areas and
how they change during chronic nicotine infusion and its withdrawal (III).
To characterise the different nAChR subtypes that mediate nicotine-induced Fos
protein expression in the brain (IV).
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4. MATERIALS AND METHODS
4.1. Animals
Male Wistar rats (Laboratory Animal Centre, University of Helsinki) were
housed four to a cage at an ambient temperature of 20-23°C before the
experiments. A 12h:12h light- dark cycle was imposed with lights on at 0600 h.
Standard rat chow and tap water were available ad libitum. During the
experiments, the rats were housed singly to a cage. The experimental protocols
were approved by the Committee for Animal Experiments of the Faculty of
Science of the University of Helsinki (III, IV) and by the chief veterinarian of the
county administrative board (I, II). All experiments were conducted according to
the “European Convention for the Protection of Vertebrate Animals used for
Experimental and other Scientific Purposes”.
4.2. Drugs
nAChR agonists: for subcutaneous injections, (-)-nicotine base (Fluka Chemie
AG, Buchs, Switzerland) was diluted with 0.9% NaCl (saline) and the pH was
adjusted to 7.0-7.4 with 0.05 M HCl. Epibatidine hydrochloride (Research
Biochemicals International, Natick, MA, USA) was dissolved in saline. Both
were administered in a volume of 1 ml/kg. For chronic experiments, nicotine
hydrogen tartrate (Sigma, St. Louis, MO, USA) was used (see paragraph 4.7.).
nAChR antagonists: for intraperitoneal injections, mecamylamine hydrochloride
(Merck, Sharp Dohme B.V. Haarlem, Netherlands), dihydro-beta-erythroidine
hydrobromide (DHE) and methyllycaconitine citrate (MLA, Research
Biochemicals International, Natick, MA, USA) were dissolved in saline and
given in a volume of 2 ml/kg.
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Halothane anesthesia was used during implantation of microdialysis probes (I, II)
as well as during minipump implantation and removal (III). During intracranial
surgery, local lidocaine anesthesia was additionally used. Sodium pentobarbital
solution (Mebunat

 60 mg/ml, Orion Farmos, Turku, Finland) was used for
anesthesia when performing the immunohistochemical experiments (III, IV).
4.3. Measurement of rectal temperatures (I)
Rectal temperatures in rats were measured with an electric thermocouple (Ellab
Instruments, Copenhagen, Denmark) inserted 5 cm into the rectum. Temperatures
were obtained before the injection of saline or nicotine and at 30, 60, 120 and 180
min after the s.c. injections.
4.4. Measurement of serum corticosterone concentrations (I)
Serum corticosterone concentrations were measured from rats implanted with
microdialysis probes and kept at either 20-23 or 30-33
C for two days. Between
0930-1000 h the rats were given s.c. saline or nicotine and killed by decapitation
60 min later. The timing was identical to microdialysis experiments in order to
avoid corticosterone fluctuations due to the circadian rhythm. Trunk blood was
collected into iced tubes, immersed in ice for 30 min, and the serum was
separated by centrifugation. The samples were stored frozen at -80
C until
assayed. Serum corticosterone concentrations were measured in duplicates using
the Immuchem
TM
 double antibody 
125
I radioimmunoassay obtained from ICN
Biomedicals Incorporation (Costa Mesa, CA, USA).
4.5. In vivo microdialysis (I, II)
In experiments described in (I) rats were implanted with self-made modified I-
shaped microdialysis probes (Ruotsalainen and Ahtee 1996) under stereotaxic
guidance under general halothane and local lidocaine (5.0 mg ml
-1
) anaesthesia.
The exposed length of dialysis membrane of the probes was 4 mm. Coordinates
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for probe implantation were calculated relative to bregma and dura (A + 1.0, L +
2.7, D -6.0 ) according to the atlas of Paxinos and Watson (1986). After the
surgery the rats were kept at an ambient temperature of either 20-23
C or 30-
33
C, and the microdialysis experiments were performed approximately 42 - 46 h
later.
On the day of the experiment, the implanted probes were connected to a
microperfusion pump. The pump was set to a perfusion speed of 2 	l min-1 and
the rats were allowed to equilibrate for at least 1 h. Following this interval,
dialysate samples (40 	l) were collected every 20 min. The perfusion medium
was a modified Ringer solution containing in mM: NaCl 147.0, CaCl
2
 1.2, KCl
2.7, MgCl
2
 1.0 and ascorbic acid 0.04. Nicotine or saline was administered after a
stable outflow of DA and its metabolites was established as shown by at least 3
consecutive samples. A 20 	l aliquot of each sample was injected into the
chromatograph with a CMA/200 autoinjector (CMA, Stockholm, Sweden).
Concentrations of DA, DOPAC and HVA were assayed using an ESA
Coulochem 5100A detector (ESA Inc., MA, USA) equipped with a model 5014A
microdialysis cell and a Pharmacia LKB model 2150 pump (Pharmacia LKB,
Sweden). The column (Spherisorb ODS2, 4.6 x 100 mm) was kept at 40
C with a
column heater (Croco-Cil, France). The mobile phase (pH 4.0) consisted of a
mixture of 0.1 M NaH
2
PO
4
, 0.1 M citric acid, methanol 18-20%, 0.8-1.6 mM
octanesulphonic acid and 0.2 mM EDTA. Correct placement of the dialysis
probes was verified visually from coronal sections cut from brains fixed with
formalin.
In experiments described in (II), the self-made microdialysis probes were
replaced with commercial ones inserted via guide cannulae (Bioanalytical
Systems Inc., USA). The coordinates for cannula implantation (BAS MD-2250)
aimed at the NAcc were A/P = + 1.7; L/M = + 1.4; D/V = -6.3 and those aimed at
the CPu were A/P = + 1.0; L/M = + 2.7; D/V = -2.0, from the bregma according
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to the atlas of Paxinos and Watson (1986). After the surgery, the rats were placed
individually into test cages and allowed to recover for 6-7 days at an ambient
temperature of 20-23
C. On the experimental day, a microdialysis probe (BAS
MD-2200, membrane length = 2.0 mm or BAS MD-2204, membrane length = 4.0
mm for the NAcc and CPu, respectively) was inserted into the cannula. Thus, the
final locations of the tips of the microdialysis probes inserted via the cannulae
were D/V -8.3 and -6.0 for the NAcc and CPu, respectively. The analytical
procedure for the estimation of DA, DOPAC and HVA concentrations was
similar to that described in (I).
4.6. Measurement of nicotine and cotinine concentrations (I, III)
For the measurement of nicotine concentrations in the brain (I), rats were killed
by decapitation 60 min after nicotine injection (0.5 mg/kg s.c.). The brains were
removed and placed on a brain mould (RBM-4000C, ASI Instruments, USA), and
coronal slices were cut between 2.70 mm and -4.70 mm from bregma. The slices
were immediately weighed and homogenised in 0.05 M HCl in 3.0 ml g
-1
 of brain
tissue. Nicotine concentrations in the homogenates were measured by modifying
the methods of Leikola-Pelho et al. (1990) and Deutch et al. (1992). In brief, 100
ng of quinoline in water was added as an internal standard (I.S.) in 1.0 ml of
homogenate. The samples were alkalinised with 1.0 ml of 5 M NaOH and
extracted with n-butyl chloride (2.5 ml). The n-butyl chloride extract was
acidified with 1.0 ml 1 M HCl and the organic solvent was removed. The
remaining aqueous phase was treated with 200 	l of 5 M NaOH and extracted
with chloroform (400 	l). After centrifugation, most of the aqueous layer was
discarded and the remaining water was removed by freezing the samples
overnight at -20
C. Subsequently, the unfrozen organic layer was transferred to a
2 ml septum cap vial and the chloroform was evaporated under nitrogen gas. Of
the remaining solution (20 	l), 2-3 	l were injected into the gas chromatograph-
mass spectrometer (GC-MS) system. Analyses were performed on a Hewlett-
Packard 5970 quadropole MS coupled to a Hewlett-Packard 5890 GC using a
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NB-54 fused silica column (15 m). Fragment ions of m/z 84 (nicotine), 129
(quinoline, I.S.) and 98 (cotinine) were used for single ion monitoring. Sensitivity
of this assay was 10 ng ml
-1
 and the correlation coefficient of the standard
samples (mouse brain tissue) between 25 and 300 ng ml
-1
 was 0.989. Coefficient
of variation (reproducibility) of the method was 4.8% (n=3) for nicotine at the
concentration of 100 ng ml
-1
 homogenate.
For the measurement of nicotine and cotinine concentrations in the plasma of rats
(III), trunk blood was collected after decapitation. The plasma was separated by
centrifugation and the samples were stored at - 80
C until assayed. The samples
were prepared as decribed previously (Curvall et al., 1982; Leikola-Pelho et al.,
1990; Pekonen et al., 1993). The procedure was identical to analysis of brain
tissue except for that only one extraction step is required.
Nicotine contamination from external sources, such as atmosphere, reagents and
apparatus can significantly complicate interpretation of analysis results. To
minimise external contamination, the working area was wiped with ethanol and
all laboratory equipment was rinsed with ethanol and kept in an oven at 40-100
C
for at least 12 h before use.
4.7. Chronic administration of nicotine (III)
Rats were implanted with Alzet

 osmotic minipumps (model 2001) releasing
saline or nicotine 4 mg/kg/day for 7 days. The dose refers to the nicotine base.
The concentration of nicotine was adjusted to compensate for differences in the
body weight of the subjects. Before implantation each pump was primed
overnight in saline at 37
C. Withdrawal was induced by removing the minipumps
surgically on the 7th day of chronic treatment.
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4.8. Measurement of dopamine and its metabolites from tissue samples (III)
The rats were decapitated and the striatum and the limbic forebrain (containing
inter alia the olfactory tubercles, medial part of the nucleus accumbens, the
central nucleus of amygdala, and part of the paleocortex) were dissected and
collected on dry ice within 5 minutes. Tissues were weighed and stored at -80°C
until assayed. The striatal and limbic concentrations of DA and its metabolites,
DOPAC and HVA, were measured by high-performance liquid chromatography
(HPLC) with electrochemical detection after Sephadex G-10 gel chromatographic
clean-up of samples. Tissue samples were homogenised in 1.0 ml 0.2 M HClO
4
,
and pH of the homogenates was adjusted to 2.4 by KOH/HCOOH buffer. After
centrifugation (15 min, 28 000 x g, 4
C), 1.0 ml of the supernatant was injected
into an acidic (0.01 M HCl) Sephadex G-10 column (bed height 8 mm) prepared
in a long Pasteur pipette. After the supernatants had passed through the columns,
the compounds were eluted, and 200 	l of each collected fraction was injected
through a high-pressure injection valve in a HPLC column. The C-18 reverse
phase (Spherisorb ODS 2 m) HPLC column (25 cm, 4.6 mm i.d.) was connected
to the electrochemical detector (Coulochem II, ESA). Detailed description of the
method has been presented in Haikala (1987).
4.9. Fos immunohistochemistry (III, IV)
Rats were anaesthetised with sodium pentobarbital (120 mg/kg i.p.) and perfused
intracardially with 100 ml of phosphate-buffered saline (PBS) followed by 200
ml of 4% paraformaldehyde in 0.1 M sodium phosphate buffer pH 7.4. The brains
were removed, postfixed for 4 h and stored in sodium phosphate buffer
containing 20% sucrose at 4
C for 2-7 days. Coronal sections (40 	m) were cut
on a cryostat (Leica CM 3050, Leica Instruments GmbH, Nussloch, Germany).
Three adjacent free-floating sections from selected brain areas were stained using
standard immunohistochemical procedures. Brains from 4 animals were
processed at a time and animals from different treatment groups were included in
every run.
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In Paper III, the sections were first incubated in 2% normal rabbit serum (NRS,
Vector Laboratories, Burlingame, CA, USA; in PBS + 0.5% Tween 20 + 0.2%
NRS) for 60 min to block non-specific staining. The sections were then incubated
in primary fos-antibody (OA-11-824, Genosys Biotechnologies Inc., Cambridge,
UK) diluted in 1:1000 or 1:2000 in PBS (in 0.5% Tween 20 + 4% NRS) for 72 h
at 4C. The antibody used was sheep polyclonal antibody to fos oncoproteins to a
synthetic peptide Met-Phe-Ser-Gly-Phe-Asn-Ala-Asp-Tyr-Glu-Ala-Ser-Ser-Ser-
Arg-Cys, selected from a conserved region of mouse and human c-fos (van
Straaten et al., 1983). The sections were processed with the avidin-biotin method
(Vectastain Kit, Vector Laboratories, Burlingame, CA, USA) with
diaminobenzidine (Sigma Chemicals, St.Louis, MO, USA) as the chromagen.
The sections were then mounted on gelatine/chrome alume-coated slides, air
dried, dehydrated through graded ethanols to xylene and coverslipped with DePex
(BDH Laboratory Supplies, Poole, England). Controls for the immunostaining,
which included omission of either primary or secondary antibody, demonstrated
no Fos-immunostaining. The atlas of Paxinos and Watson (1986) was used to
identify the brain areas. The Fos-positive nuclei were counted with a 10 x
objective with the assistance of a LEICA QWin image analysis system on
selected brain areas within a rectangular area of 480 x 360 m. A group mean (
S.E.M) was determined from the counts of 4-7 rats in each treatment group. The
performance of the computerised system was checked by manually counting
randomly selected sections.
In Paper IV, a different primary antibody was used due to problems with the
quality of new lots of OA-11-824. Briefly, sections were first rinsed in PBS for
10 min, treated with 0.5% hydrogen peroxide for 10 min and rinsed again in PBS
for 3x10 min. Sections were then incubated with 3% normal goat serum (NGS)
for 60 min in order to block nonspecific staining. Thereafter, sections were
incubated with a polyclonal rabbit antibody to Fos (Calbiochem
®
 Cat# PC38,
Oncogene Research Products) diluted 1:2000 in PBS containing NGS (3%),
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Tween 20 (0.5%) and sodium azide (0.1%) for 20-22h at room temperature under
gentle shaking. The sections were then washed in PBS for 2x10 min, in PBS +
Tween 20 (0.5%) + NGS (1.5%) for 15 min and incubated for 2 h with the sheep
anti-rabbit biotinylated antibody (Vectastain
®
 Elite ABC Kit PK-6101) at room
temperature. The immunoreactivity was revealed as described above. Fos-like
immunoreactive nuclei were quantified using a different image analysis system
than in III. The new system included a camera (COHU High Performance CCD
Camera, Cheos Corporation, Finland), a microscope (Nicon Eclipse TE300,
Nicon Corporation, Tokyo, Japan) and a PC computer with Image-Pro Plus 4.0
software (Media Cybernetics, L.P, Silver Spring, USA).
4.10. Statistics
Changes in rectal temperatures were compared with 2-way (dose x temperature
interaction) analysis of variance (ANOVA) for repeated measurements (I). The
data from microdialysis studies were subjected to either 1-way (epibatidine and
nicotine dose-response studies) or 2-way (dependence of nicotine’s effects on
ambient temperature) ANOVA for repeated measurements. When appropriate,
multiple comparisons were conducted using the contrast analysis with Bonferroni
levels. The basal values of DA, DOPAC and HVA (I) as well as nicotine
concentrations in plasma (III) and brain (I) were compared using Student’s t-test.
The concentrations of dopamine and its metabolites in tissue samples (III) were
compared by 3-way analysis of variance (experiment x chronic treatment x acute
treatment). Chronic x acute nicotine interactions were considered significant at P
< 0.1. Linear contrasts were used to compare means between different treatment
groups.
Serum corticosterone levels at different ambient temperatures (I) and the number
of Fos positive nuclei (III, IV) were compared using the Kruskall-Wallis non-
parametric ANOVA and Mann-Whitney U-test (III, IV).
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5. RESULTS
5.1. Effects of nicotine and elevated ambient temperature on the rectal
temperature of rats (I)
The mean rectal temperature of rats kept at 20-23
C measured before
administration of nicotine or saline was 37.6  0.07
C and that of rats kept at 30-
33
C, 37.7  0.11
C, respectively (n = 15 in both groups). The rectal
temperatures of rats given saline or nicotine (0.5 or 0.8 mg/kg s.c.) during the 3-h
testing period are shown in Fig. 5-1.
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saline 0-33°C
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Figure 5-1. The rectal temperatures of rats given saline or nicotine (0.5 or 0.8 mg/kg
s.c.) at different ambient temperatures (20-23C or 30-33C). The means  SEM of 5
rats in each group are shown.
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5.2. Effects of nicotine and elevated ambient temperature on the serum
corticosterone concentration of rats (I)
Nicotine administered acutely (0.5 mg/kg) elevated the serum corticosterone
concentrations of rats significantly and to a similar level at 20-23
C and 30-33
C
(Fig. 5-2). Furthermore, the serum corticosterone concentrations in saline-treated
rats were comparable at both ambient temperatures (p > 0.33, Student’s t-test; n =
6 in all groups).
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Figure 5-2. Serum corticosterone levels (mean  SEM) in rats 60 min after acute
nicotine (0.5 mg/kg s.c.) or saline.
5.3. Nicotine and cotinine concentrations in the brain tissue and plasma of
rats (I, III)
The plasma concentrations of nicotine and cotinine were measured in rats given
nicotine acutely (0.5 mg/kg s.c.) during chronic saline or nicotine infusion as well
as after 24 h withdrawal from the chronic treatment (III). Cerebral nicotine
concentrations were measured in naïve rats given nicotine acutely (0.5 mg/kg
s.c.) either at the ambient temperature of 20-23°C or 30-33°C (I). The results are
summarised in Table 5-1. The acute nicotine dose 0.5 mg/kg elevated the plasma
nicotine concentration in saline-infused rats to a level similar to that observed in
rats on the 7
th
 day of chronic nicotine infusion (7 d nicotine + acute saline-treated
rats). When acute nicotine was given to nicotine-infused rats with nicotine-
53
releasing minipumps still in place, the further increase in plasma nicotine
concentrations was less than the additive effect of acute + chronic treatments.
Furthermore, no further increase of plasma cotinine concentration was observed.
After 24-h nicotine withdrawal, no nicotine and only traces of cotinine were
found in the plasma and acute nicotine injection (0.5 mg/kg) elevated plasma
concentrations to similar levels as those observed in naïve rats. The cerebral
nicotine concentrations of naïve rats given nicotine (0.5 mg/kg s.c. 60 min before
decapitation) displayed similar levels of elevation at both ambient temperatures
studied.
Table 5-1. Nicotine and cotinine concentrations in the brain tissue and plasma of rats
given nicotine (0.5 mg/kg s.c.) 60 min before collection of samples.
Treatment
Plasma concentration
(ng/ml)
Nicotine Cotinine
7 d saline infusion +
saline
0 0
7 d saline infusion +
nicotine 0.5
80 ± 22 103 ± 25
7 d nicotine infusion +
saline
76 ± 7 858 ± 142
7 d nicotine infusion +
nicotine 0.5
114 ± 24 639 ± 106
nicotine withdrawal 24 h +
saline
0 22 ± 12
nicotine withdrawal 24 h +
nicotine 0.5
78 ± 6 119 ± 15
Treatment
Cerebral concentration
(ng/g)
Nicotine Cotinine*
Acute nicotine 0.5
20-23C
185.5 ± 15.7 (+)
Acute nicotine 0.5
30-33C
148.4 ± 16.6 (+)
*Traces of cotinine were detected, but could not be properly quantified.
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5.4. Effects of elevated ambient temperature on nicotine-induced changes of
extracellular DA, DOPAC and HVA concentrations in the dorsal striatum
(I)
The elevation of ambient temperature had no effect on the basal extracellular
striatal concentrations of DA or its metabolites as shown in Table 5-2 (Student’s
t-test).
Table 5-2. Concentrations of DA, DOPAC and HVA (mean  SEM) in the three (basal)
dialysate samples collected before drug administration in the dorsal striatum (CPu).
Temperature DA (fmol/min) DOPAC (pmol/min) HVA (pmol/min)
20-23°C;
n= 25
14.80  0.53 0.75  0.02 0.61  0.02
30-33°C;
n = 24
13.35  0.36 0.72  0.01 0.65  0.01
The effects of nicotine and ambient temperature (20-23°C or 30-33°C) on the
extracellular concentrations of DA and its metabolites in the dorsal striatum
(CPu) are shown in Table 5-3. 2-way ANOVA revealed that nicotine treatment
(dose x time interaction; where time = 100-360 min) significantly altered the
extracellular levels of DA (F=2.04, P<0.001), DOPAC (F=4.34, P0.0001) and
HVA (F=5.24, P0.0001). Multiple comparisons showed that the smallest dose of
nicotine studied (0.3 mg/kg) did not significantly alter the extracellular DA
concentration at either ambient temperature. Furthermore, larger nicotine doses
(0.5 or 0.8 mg/kg) did not have significant effects on DA output at 20-23°C, but
at the elevated temperature these doses significantly increased the extracellular
DA concentration. The maximal elevations were found to be similar (138% after
0.5 mg/kg and 136% after 0.8 mg/kg of nicotine, respectively)
As shown in Table 5-3, the changes in levels of DA metabolites to nicotine were
only marginally enhanced by elevating the ambient temperature above 20-23
C.
Significant temperature-dependent differences we only found at the smallest
nicotine dose tested (0.3 mg/kg; see Table 5-3).
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Table 5-3. The nicotine-induced increases of the extracellular concentrations of DA,
DOPAC and HVA in the dorsal striatum (CPu) of rats kept at different ambient
temperatures (20-23°C or 30-33°C).
Treatment DA DOPAC HVA
Nicotine
0.3 mg/kg
  
Nicotine
0.5 mg/kg
  20-23°C
Nicotine
0.8 mg/kg
  
Nicotine
0.3 mg/kg
  
Nicotine
0.5 mg/kg
  30-33°C
Nicotine
0.8 mg/kg
  
 P < 0.05;  P < 0.01;  P < 0.001;  P < 0.0001 vs. saline-treated rats (2-way
ANOVA followed by multiple comparisons; n = 6-7 in all groups). A dash (	) indicates
that the effect of nicotine was not statistically significant.
5.5. Effects of elevated ambient temperature on nicotine-induced changes of
extracellular DA, DOPAC and HVA concentrations in the ventral
striatum (unpublished data)
In accordance with measurements taken in the dorsal striatum, the elevation of
ambient temperature had no effect on the basal extracellular concentrations of
DA or its metabolites in the NAcc as shown in Table 5-4 (Student’s t-test).
Table 5-4. Concentrations of DA, DOPAC and HVA (mean  SEM) in the three (basal)
dialysate samples collected before drug administration in the ventral striatum (NAcc).
Temperature DA (fmol/min) DOPAC (pmol/min) HVA (pmol/min)
20-23°C;
n= 19
0.37  0.03 0.13  0.01 0.08  0.01
30-33°C;
n = 23
0.45  0.02 0.11  0.01 0.08  0.01
Figure 5-3 demonstrates that in contrast to the dorsal striatum (CPu), elevation of
the ambient temperature did not enhance nicotine-induced elevation of
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extracellular DA concentration in the ventral striatum (NAcc), and even tended to
reduce nicotine-induced elevations of extracellular DOPAC and HVA.
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Figure 5-3. Effects of acute nicotine (0.3 or 0.8 mg/kg s.c.) on the extracellular
concentrations of DA, DOPAC and HVA in the NAcc (ventral striatum) of rats kept at
different ambient temperatures (20-23C vs 30-33C). Statistically significant changes
are summarised in Table 5-5.
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Table 5-5. The nicotine-induced increases of the extracellular concentrations of DA,
DOPAC and HVA in the ventral striatum (NAcc) of rats kept at different ambient
temperatures (20-23°C or 30-33°C)
Treatment DA DOPAC HVA
nicotine
0.3 mg/kg
  
20-23°C
nicotine
0.8 mg/kg
  
nicotine
0.3 mg/kg
  
30-33°C
nicotine
0.8 mg/kg
  
 P < 0.05;  P < 0.01;  P < 0.001;  P < 0.0001 vs. saline-treated rats (2-way
ANOVA followed by multiple comparisons; n = 6-7 in all groups.) A dash ( 	) indicates
that the effect of nicotine was not statistically significant.
5.6.  Effects of nAChR antagonists on nicotine-induced increases of DA,
DOPAC and HVA concentrations at the elevated ambient temperature (I)
As shown in Table 5-6, blockade of nAChRs by DHE or mecamylamine either
reduced or fully prevented nicotine-induced increases of DA, DOPAC and HVA
in the dorsal striatum (CPu) at 30-33
C.
Table 5-6. The nicotine-induced increases of the extracellular concentrations of DA,
DOPAC and HVA in the dorsal striatum (CPu) of rats kept at 30-33°C and pretreated
with saline, DH
E (2.8 mg/kg i.p.) or mecamylamine (mec; 5.0 mg/kg i.p.)
Treatment DA DOPAC HVA
saline + nicotine 0.5 mg/kg   
saline + nicotine 0.8 mg/kg   
DH
E + nicotine 0.5 mg/kg   
DH
E + nicotine 0.8 mg/kg   
mec + nicotine 0.5 mg/kg   
mec + nicotine 0.8 mg/kg   
 increase by more than 15%;  increase by more than 30%;  increase by more
than 45%. A dash (	) indicates statistically significant inhibition of nicotine’s effects by
DH
E or mecamylamine (2-way ANOVA followed by multiple comparisons; n = 5-7 in
all groups.).
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5.7. Effects of epibatidine on the extracellular DA, DOPAC and HVA
concentrations in the dorsal and ventral striatum of rats (II and
unpublished data); comparison to the effects of nicotine
In Table 5-7 are summarised the effects of epibatidine (1.0, 3.0 or 10.0 	g/kg) on
the extracellular concentrations of DA, DOPAC and HVA in the dorsal striatum
(CPu) and in the ventral striatum (NAcc).
Table 5-7. Epibatidine-induced increases of the extracellular concentrations of DA,
DOPAC and HVA in the dorsal (CPu) and ventral striatum (NAcc) of rats.
Area Treatment DA DOPAC HVA
epibatidine 1.0 	g/kg ND ND ND
epibatidine 3.0 	g/kg   Dorsal
epibatidine 10.0 	g/kg   
epibatidine 1.0 	g/kg   
epibatidine 3.0 	g/kg   ()Ventral
epibatidine 10.0 	g/kg ND ND ND
 P < 0.05;  P < 0.01 vs. saline-treated rats (1-way ANOVA; n = 5-8 in all groups.);
ND = not determined. A dash ( 	 ) indicates that the effect of epibatidine was not
statistically significant.
Due to the switch from self-made to commercial microdialysis probes between
studies I and II, the experiments describing the effects of nicotine on DA and its
metabolites had to be repeated. Table 5-8 summarises the effects of nicotine on
DA output and metabolism in the dorsal and ventral striatum using the
commercial probe similar to that used in experiments where epibatidine was used.
Table 5-8. The nicotine-induced increases of the extracellular concentrations of DA,
DOPAC and HVA in the dorsal (CPu) and ventral striatum (NAcc) of rats.
Treatment DA DOPAC HVA
Dorsal nicotine 0.5 mg/kg   
nicotine 0.3 mg/kg ()  
Ventral
nicotine 0.5 mg/kg   
 P < 0.05;  P < 0.01 vs. saline-treated rats (1-way ANOVA; n = 5-6 in all groups.).
A dash (	) indicates that the effect of nicotine was not statistically significant.
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5.8. Effects of acute nicotine on the concentrations of DA, DOPAC and HVA
in the striatal and limbic brain tissue during chronic nicotine infusion
and its withdrawal: correlation with Fos protein expression (III)
Table 5-9 summarises the observed changes of the effects of an acute nicotine
challenge in rats during a 7-day chronic nicotine infusion and in withdrawn
animals. It is of note that striatal and limbic DA concentrations were not altered
by any of the treatments. In saline-infused (naïve) rats, nicotine 0.5 mg/kg s.c.
significantly elevated the striatal and limbic DOPAC and HVA concentrations.
When acute nicotine was given during chronic nicotine infusion, the elevations of
striatal DOPAC and HVA and limbic DOPAC were completely abolished but the
increase of limbic HVA persisted. After 24h withdrawal, acute nicotine elevated
striatal DOPAC and HVA and limbic HVA, but limbic DOPAC was unaffected.
After 72h withdrawal, acute nicotine’s effects on striatal and limbic DOPAC and
HVA were fully restored. Chronic nicotine infusion alone did not alter striatal
DOPAC and HVA, but the limbic HVA concentration was significantly elevated
in rats on the 7
th
 day of nicotine infusion.
Table 5-9. Changes of DA metabolism and Fos protein expression in response to acute
and chronic nicotine treatment
Dopamine metabolism
Treatment
Striatal Limbic
Fos expression
DOPAC HVA DOPAC HVA Cg NAcc CPu CeA
7 d saline infusion +
nicotine 0.5
       
7 d nicotine infusion +
nicotine 0.5
- - -    - 
Nicotine withdrawal 24 h
+ nicotine 0.5
 - -  - - - 
Nicotine withdrawal 72 h
+ nicotine 0.5
       
- = no change;  P < 0.05;  P < 0.01;  P < 0.001;  P < 0.0001 vs. saline-
treated rats (3-way ANOVA followed by contrast analysis or Kruskall-Wallis non-
parametric ANOVA followed by Mann-Whitney U-test). CeA = central nucleus of
amygdala; Cg = cingulate cortex; CPu = dorsomedial caudate-putamen; NAcc = core of
nucleus accumbens.
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Table 5-9 also summarises the observed changes in the expression of Fos protein
by acute nicotine administration during continuous nicotine infusion and its
subsequent withdrawal. In saline-infused rats, acute nicotine increased Fos IS in
all brain regions studied. During continuous nicotine infusion, the effect of an
acute challenge (0.5 mg/kg) was attenuated in the CPu and NAcc, but not in the
Cg and CeA. After 72 h withdrawal, nicotine’s effects were fully restored.
Neither nicotine infusion itself nor removal of the nicotine-containing minipumps
elevated Fos IS in any of the brain areas studied.
5.9. Effects of nAChR antagonists on nicotine-induced Fos protein expression
(IV)
Table 5-10 shows that the nAChR antagonists DHE, mecamylamine (especially
the larger doses tested) or MLA significantly increased Fos IS in several of the
brain areas studied.
Table 5-10. Number of Fos-positive nuclei (mean  SEM) in eleven different brain
regions of rats treated with different nAChR antagonists (i.p.) and saline (s.c.).
Brain
area
Treatment
sal +
sal
sal +
mec 1.0
sal +
mec 5.0
sal +
DHE 1.4
sal +
DHE 2.8
sal +
mla 4.0
mPFC
47  13 70  15 54  7 68  13 91  12 53  6
Cg
40  3 37  5 79  8** 62  7* 83  5** 55  12
Par
6  2 29  9* 28  7* 28  8* 19  7 8  2
NAcc
42  9 66  11 51  11 53  13 43  8 34  6
CPu
20  4 27  4 23  4 52  10* 77  17* 59  9*
CeA
38  6 85  11** 93  15** 41  6 32  3 97  13*
IPN
2  0 5  1 11  2** 6  1* 10  3** 4  1
PVN
52  5 87  17 151  19** 82  19* 98  4* 70  15
SON
8  4 5  1 108  8** 10  4 6  2 4  1
MT
3  0 2  0 3  1 2  0 2  1 4  1
SuG
12  3 15  3 43  4** 31  4* 59  8** 54  12*
*P<0.05; **P<0.01 vs. saline-treated rats (Mann-Whitney U-test; n = 5-8); sal = saline;
mec 1.0 = mecamylamine 1.0 mg/kg; mec 5.0 = mecamylamine 5.0 mg/kg; DH
E 1.4 =
dihydro-
-erythroidine 1.4 mg/kg; DH
E 2.8 = dihydro-
-erythroidine 2.8 mg/kg; mla
4.0 = methyllycaconitine 4.0 mg/kg; mPFC = medial prefrontal cortex; Cg = cingulate
cortex; Par = parietal cortex; NAcc = core of nucleus accumbens; CPu = dorsomedial
caudate-putamen; CeA = central nucleus of the amygdala; IPN = interpeduncular
nucleus; PVN = paraventricular hypothalamic nucleus; SON = supraoptic hypothalamic
nucleus; MT = medial terminal nucleus of the optic tract; SuG = superficial gray layer of
the superior colliculus.
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As shown in Table 5-11, acute nicotine administration (0.5 mg/kg s.c.)
significantly increased Fos IS in ten out of the eleven regions investigated,
excluding the medial prefrontal cortex. In eight of the regions studied one or
more of the three antagonists caused a significant decrease of nicotine-induced
Fos IS.
Table 5-11. Number of Fos-positive nuclei (mean  SEM) in eleven different brain
regions of rats pretreated with different nAChR antagonists (i.p.) and given nicotine (0.5
mg/kg s.c.).
Brain
area
Treatment
sal
+ nic
mec 1.0
+ nic
mec 5.0
+ nic
DHE1.4
+ nic
DHE 2.8
+ nic
mla 4.0
+ nic
MPFC
65  9 82  14 51  9 71  10 88  14 94  13
Cg
77  8** 67  6 76  8 74  12 56  7 96  8
Par
60  14** 47  9 64  19 17  3

27  8 82  21
NAcc
97  6** 79  12 30  8

79  12 36  8

91  16
CPu
58  5** 33  5

33  6

57  10 59  5 85  16
CeA
130  11** 105  7 100  5 111  18 100  36 103  17
IPN
285  14** 52  12

13  2

198  10

146  16

272  30
PVN
438  23** 133  23

177  27

346 48 228  45

389  29
SON
62  9** 13  6

134  17

43  10 34  10

31  6

MT
110  10** 3  0

3  1

111  8 73  14

68  16

SuG
196  16** 43  4

38  10

174  15 115  14

173  24
*P<0.05; **P<0.01 vs. saline-treated rats (Mann-Whitney U-test; n = 5-8); P<0.05;
P<0.01 vs. nicotine-treated rats; nic = nicotine; for further abbreviations see Table 5-
10.
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6. DISCUSSION
6.1. Effects of nicotine and elevated ambient temperature on the rectal
temperature of rats (I)
In the present experiments, elevating the temperature of the animal room by 10
degrees had no effect on the rectal temperatures of saline-treated rats which is in
agreement with a recent report by Vuckovic et al., (1998). Furthermore, none of
the nicotine doses tested decreased the rectal temperature of rats kept at either 20-
23
C or 30-33
C. Many earlier studies have shown that acute nicotine injections
induce hypothermia in mice and rats (Mansner et al., 1974; Horstmann 1984), and
that this effect can be counteracted by elevating the ambient temperature of their
environment (Haikala et al., 1986; Leikola-Pelho et al., 1990). Interestingly, there
seems to be a correlation between the degree of hypothermia and sensitivity to
nicotine’s toxic effects, i.e. the higher the nicotine doses the animals tolerate, the
more pronounced is the decrease in rectal temperature at the normal room
temperature (20-25
C). In general, mice seem to tolerate larger nicotine doses
than rats. In our preliminary experiments, nicotine’s toxic effects were obvious at
the dose of 1.0 mg/kg at 20-23
C indicating that Wistar rats seem to be especially
sensitive to nicotine-induced toxicity. It is hypothetised that this occurs because
the hypothermia-inducing protective mechanism is not activated.
6.2. Effects of nicotine and elevated ambient temperature on the serum
corticosterone concentration of rats (I)
Evidence exists that glucocorticoids modulate the effects of nicotine (Johnson et
al., 1995) and that steroid hormones act as allosteric modulators at nAChRs (Ke
and Lukas 1996). Furthermore, exposure to stressful stimuli or administration of
glucocorticoids are known to increase DA release in vivo (Abercrombie et al.,
1989; Piazza et al., 1996). Therefore, the serum corticosterone concentrations
were measured to elucidate if nicotine-induced DA release at the elevated
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ambient temperature was simply due to altered corticosterone release in response
to heat. Under resting conditions at standard room temperature, the serum
corticosterone concentrations in mice and rats has been found to vary between 50
and 300 ng/ml
 
depending on experimental conditions (Shimizu et al., 1983).
Thus, the serum corticosterone concentrations below 100 ng/ml obtained in
saline-treated rats at both ambient temperatures studied (20-23
C and 30-33
C)
indicate that implantation of microdialysis probes and exposure to elevated
ambient temperature did not induce neuroendocrine stress by themselves.
Furthermore, acute nicotine treatment significantly elevated the serum
corticosterone concentrations to a similar level at both ambient temperatures
studied, and therefore it is unlikely that the differences in nicotine´s effects on
striatal DA release at different ambient temperatures are stress-related. However,
the study of Takahashi et al. (1998) showed that in the striatum, stress enhances
DA release that was induced by locally applied nicotine and that chronic nicotine
treatment combined with a stressful stimulus (electric footshock) significantly
increases DA release whereas neither chronic nicotine or stress alone had any
effect. Thus, stressful stimuli may modulate the effects of nicotine under some
experimental conditions, and the differences between the results of Takahashi et
al. (1998) and the present findings could be explained by the use of stressors of
different intensity, duration of nicotine treatment (chronic vs. acute), and route of
administration (local infusion vs. systemic injection).
6.3. Nicotine and cotinine concentrations in the brain tissue and plasma of
rats (I, III)
The nicotine concentrations found in the plasma (80 ± 22 ng/ml; III) and brain
tissue (186 ± 16 ng/g at 20-23°C; I) of rats following a single injection (0.5
mg/kg s.c.) correspond to those encountered in humans after smoking several
cigarettes (Benowitz et al., 1990; Gourlay and Benowitz 1997). In agreement
with the present data, Benowitz (1988) reported that the brain/blood nicotine
concentration ratio was about 3. Elevation of the ambient temperature in Study I
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did not result in higher brain nicotine concentrations following s.c.
administration, although Vanakoski et al., (1996) have shown that in humans,
exposure to high temperatures increases absorption of transdermal nicotine.
Constant nicotine infusion via Alzet
®
 osmotic minipumps has been widely used
as a model of nicotine dependence (Malin et al., 1992; Benwell et al., 1995;
Hildebrand et al., 1997; Epping-Jordan et al., 1998). The stability of nicotine in
the minipumps has been demonstrated previously (Benwell et al., 1995). The
disadvantage of this method is that the fluctuation seen in the plasma nicotine
concentrations following cigarette smoking is not achieved, and thus, nAChR
desensitisation may be more pronounced than in habitual smokers. In the present
experiments, the mean plasma nicotine concentration on the 7
th
 day of constant
nicotine infusion (4 mg/kg/day) was 76 ± 7 ng/ml, which is in good agreement
with other studies (Benwell et al., 1995; Hildebrand et al., 1999), and indicate
that the minipumps were still releasing nicotine. Interestingly, when the nicotine-
infused rats were given nicotine acutely (0.5 mg/kg s.c.), the observed increase of
plasma nicotine concentration was less than the additive effect of acute + chronic
treatments, and the concentration of cotinine was even lower than in rats infused
with nicotine and given saline acutely. This may reflect enhanced metabolic
degradation or enhanced excretion of nicotine during chronic infusion.
6.4. Effects of elevated ambient temperature on nicotine-induced changes of
extracellular DA, DOPAC and HVA concentrations in the dorsal striatum
(I)
Previous studies have demonstrated that, in mice, nicotine’s stimulatory effects
on striatal DA metabolism are larger and are found at smaller doses when the
hypothermic effect of the drug is counteracted by elevating the ambient
temperature (Haikala et al., 1986; Leikola-Pelho et al., 1990). However, these
earlier studies were conducted by measurung post mortem tissue concentrations
of DA metabolites. Therefore, in vivo microdialysis was used in Study I to further
characterise the effect of ambient temperature on extracellular DA output. Study I
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demonstrated that nicotine (0.5 or 0.8 mg/kg) significantly enhanced striatal DA
output in rats kept at an ambient temperature of 30-33°C but not in rats kept at
20-23°C. Furthermore, the lower dose of 0.3 mg/kg
 
of nicotine significantly
elevated extracellular striatal DOPAC and HVA concentrations in rats kept at 30-
33°C but not in those kept at 20-23
C. The effects of the doses 0.5 or 0.8 mg/kg
on DOPAC and HVA levels were similar and significant at both ambient
temperatures studied. The basal striatal concentrations of DA or its metabolites
were not altered by elevating the temperature, thus indicating that the change in
ambient temperature alone did not alter striatal DA release or metabolism. The
non-significant effect of nicotine at 20-23
C on extracellular DA in the dorsal
striatum is in agreement with earlier observations from studies carried out under
similar conditions, e.g. Ca
++
 concentration of the perfusion medium was kept
within the physiological range and DA uptake was not inhibited by the use of
uptake blockers, e.g. nomifensine (Brazell et al., 1990).
Enhancement of striatal DA output by nicotine at high temperatures can most
probably be explained by increased impulse flow of dopaminergic neurons in the
SNc. DA has been implicated in thermoregulation, and electrical stimulation of
the SNc induces hypothermia in rats at ambient temperatures below 22°C, but
hyperthermia at 30°C (Clark and Lipton 1985; Lin et al., 1992; Salmi 1998)
indicating that the DA-mediated thermal response varies at different ambient
temperatures. It is also reasonable to conclude that nicotine-induced stimulatory
affects such as altered activity differ from its effect under standard room
temperature. Interestingly, there are studies to suggest that cooling prolongs the
action of depolarising neuromuscular blocking drugs and thus could alter the
functioning of nAChRs by increasing desensitisation (Zaimis and Head 1976).
Therefore, it is tempting to speculate that the temperature-dependent difference in
nicotine’s effects in Study I is due to a related phenomenon. For example, it could
be that a larger proportion of the nAChRs regulating striatal dopaminergic
neurons have undergone a conformational change leading to desensitisation at
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20-23
C than at the elevated temperature of 30-33
C. However, as discussed
below, when parallel experiments were conducted to measure DA release in the
ventral striatum (NAcc), no enhancement of nicotine’s effects on DA release or
metabolism at 30-33
C was observed. Therefore, desensitisation of nAChRs does
not fully explain the temperature-dependency of nicotine’s effects in the dorsal
striatum, although it can not be excluded that different nAChR populations may
mediate nicotine’s effects in the dorsal vs. ventral striatum.
6.5. Effects of elevated ambient temperature on nicotine-induced changes of
extracellular DA, DOPAC and HVA concentrations in the ventral
striatum (unpublished data)
In contrast to the findings concerning the dorsal striatum, elevation of the
ambient temperature did not enhance nicotine-induced DA output nor formation
of DOPAC and HVA in the ventral striatum. The “intrinsic” e.g.
electrophysiological properties of mesolimbic and nigrostriatal DA neurons, as
well as their connectivity, are markedly different, although differences in the
nAChR subtypes located on these neurons are neglible (Mereu et al., 1987;
Wightman and Zimmerman 1990; Le Novere et al., 1996; Sgard et al., 1999).
Mesolimbic and nigrostriatal DA neurons also respond differently to stressful
stimuli (Abercrombie et al., 1989; Takahashi et al., 1998). Therefore, the simplest
explanation for the present findings is that although the DA neurons projecting to
the dorsal striatum are involved in thermoregulation, the neurons of the
mesolimbic DA system projecting to NAcc are not. Accordingly, the thermic
effect of neurotensin has been observed in the hypothalamus, but not in the NAcc
(Benmoussa et al., 1996). Furthermore, these studies demonstrated that nicotine-
induced DA release in the NAcc is not prone to desensitisation when the nicotine
dose given s.c. is increased from 0.3 mg/kg to 0.8 mg/kg.
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6.6.  Effects of nAChR antagonists on nicotine-induced increases of DA,
DOPAC and HVA concentrations in the dorsal striatum at the elevated
ambient temperature (I)
The experiments utilising the antagonists DHE and mecamylamine were carried
out to verify that the nicotine-induced elevations of extracellular DA, DOPAC
and HVA in the dorsal striatum at the high temperature are actually mediated by
nAChRs. In a previous study, in which the effects of nicotine on the striatal DA
system were investigated in mice kept at different ambient temperatures, Leikola-
Pelho et al. (1990) suggested that the nAChRs involved in the regulation of
striatal DA metabolism and DA release differed from each other. Recently, other
investigators have also shown that nAChRs modulating somatodendritic and
terminal DA release differ pharmacologically (Reuben et al., 2000). The
enhancement of DA metabolism seems to be linked to the activation of nAChRs
in the somatodendritic region, because locally applied nicotine failed to increase
the extracellular concentrations of DOPAC and HVA in the striatum and nucleus
accumbens (Toth et al., 1992; Marshall et al., 1997). The findings that
mecamylamine preferentially blocked the nicotine-induced elevation of
extracellular DOPAC and HVA concentrations, whereas DHE significantly
blocked the nicotine-induced elevation of DA concentration but not that of
DOPAC or HVA, are in agreement with the proposal that the effects of nicotine
on striatal DA release are mediated by nAChRs different from those mediating
nicotine’s effects on DA metabolite levels. Thus, the studies with nAChR
antagonists suggest that the enhancement of nicotine-induced DA release at the
high temperature is mediated via nAChRs, and that nicotine’s effects on DA
release and metabolism are mediated by different nAChR subpopulations.
6.7. Effects of epibatidine on the extracellular DA, DOPAC and HVA
concentrations in the dorsal and ventral striatum of rats (II and
unpublished data); comparison to the effects of nicotine
Epibatidine is an agonist to nAChRs that has been reported to be 150-fold more
potent in stimulating DA release from rat striatal slices than (-)-nicotine (Sullivan
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et al., 1994). Due to its high affinity and lack of selectivity for the various
nAChRs (Brioni et al., 1997) it has been difficult to determine if epibatidine and
nicotine stimulate the same or different sets of nAChRs. However, epibatidine
appears not to have reinforcing effects, as it is not readily self-administered by
mice (Rasmussen and Swedberg 1998). Therefore, the purpose of Study II was to
characterise the interaction of epibatidine with the nigrostriatal and mesolimbic
DA systems. Parallel experiments with nicotine were carried out for comparison.
The dose of epibatidine used in Study II (3.0 	g/kg) is equi-effective to that of
nicotine (0.5 mg/kg) with respect to the analgesia-producing and hypothermic
effects of the drugs (Sullivan et al., 1994).
Study II demonstrated that epibatidine 3.0 	g/kg significantly enhanced DA
output in the dorsal striatum (CPu) but not in the ventral striatum (NAcc). On the
other hand, in accordance with many earlier studies, nicotine preferentially
stimulated accumbal DA output and metabolism compared with its effects in the
CPu (Imperato et al., 1986; Grenhoff and Svensson 1988). Thus, the results
suggest that the mesolimbic and nigrostriatal dopaminergic terminal regions
respond differently to nicotine and epibatidine. However, further experiments
with a smaller epibatidine dose (1.0 	g/kg s.c.) showed that epibatidine is also
able to stimulate DA release on a short timescale from the NAcc , and thus
activates the mesolimbic DA system. Epibatidine’s stimulatory effect on
mesolimbic DA is apparently more prone to desensitisation than nicotine’s, since
it disappears completely when the epibatidine dose is increased to 3.0 	g/kg.
The effects of nicotine and epibatidine on the nigrostriatal system differ as well,
although changes are in the opposite direction: nigrostriatal DA neurons are
seemingly less prone to epibatidine-induced desensitisation as judged from the
larger amount of DA released in response to epibatidine vs. nicotine. The
observed differences in the effects of epibatidine and nicotine most probably
involve differences in desensitisation, but other factors may contribute as well.
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The higher DA uptake rate in the CPu vs. NAcc is probably a contributing factor,
according to the kinetic model described by Wightman and Zimmerman (1990).
According to their measurements, the lower DA uptake rate in the latter region
dictates that, at stimulation frequencies within the physiological range, DA
overflow will be enhanced to a greater degree in the NAcc. This is in agreement
with results of Study II on nicotine, utilising smaller doses of epibatidine, but in
contrast with the stimulatory effects of higher epibatidine doses in the CPu. At
present, the preferential stimulatory effects of the higher epibatidine doses on DA
release in the CPu are difficult to explain, and the effects of epibatidine on DA
uptake and nAChR desensitisation should be analysed further.
Although epibatidine (3.0 	g/kg) only elevated the extracellular concentrations of
DA in the dorsal striatum, the extracellular concentrations of DA metabolites
were increased in both the dorsal and ventral striatal areas studied. Furthermore,
epibatidine (1.0 	g/kg) did not alter the concentrations of DA metabolites in the
ventral striatum in spite of enhanced DA output. These findings suggest that
epibatidine differentially affects DA release and metabolism in the dorsal and
ventral striatum, although part of the DOPAC and HVA collected in the ventral
striatum could have diffused from the dorsal area. This is in line with Study I, in
which the nAChRs that mediate nicotine’s effects on DA release were found to
differ from those mediating its effects on DA metabolism in the dorsal striatum.
Therefore, it is likely that epibatidine shares the ability of nicotine to
differentially effect different aspects of DA output and metabolism, probably by
activating a different subpopulation of nAChRs.
The observed differences in the responses of dopaminergic neurones to
epibatidine are important when considering the attempts to develop epibatidine
analogues and other compounds that act via nAChRs for use e.g. in pain
management and in the treatment of Parkinson’s disease. According to recent
studies, epibatidine seems to lack the rewarding effects of nicotine since it is not
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readily self-administered by mice (Rasmussen and Swedberg 1998), and
sensitisation does not develop to its locomotor stimulating effects (Reuben et al.,
2000). Furthermore, the present data suggests that the effects of epibatidine on
mesolimbic DA are short-acting and easily desensitised. Thus, novel nicotinic
AChR ligands structurally related to epibatidine may have low abuse potential.
6.8. Effects of acute nicotine on the concentrations of DA, DOPAC and HVA
in the striatal and limbic brain tissue during chronic nicotine infusion
and its withdrawal: correlations to Fos protein expression (III)
Microdialysis studies using rats have previously demonstrated that the DA-
releasing effect of acute systemic nicotine is attenuated during continuous
nicotine infusion in the CPu and NAcc suggesting desensitisation of nAChRs in
the constant presence of nicotine (Benwell et al., 1995; Benwell and Balfour
1997). Desensitisation and inactivation of nAChRs have been widely studied in
vitro (Rapier et al., 1988; Rowell and Hillebrand 1994; Fenster et al., 1997;
Rowell and Duggan 1998). Furthermore, in an in vivo study, James et al. (1994)
demonstrated that nicotine can acutely desensitise brain nAChRs. Study III
established for the first time in vivo, that nAChRs controlling midbrain DA
systems are persistently inactivated during constant nicotine infusion, as the
effect of acute nicotine on DA metabolites (especially on limbic DOPAC) was
still attenuated 24-h after the nicotine-releasing minipumps were removed.
Interestingly, on the 7
th
 day of chronic nicotine infusion, the limbic, but not
striatal, levels of HVA were elevated compared to saline-infused controls, and
acute nicotine still induced a further elevation of limbic HVA of nicotine-infused
rats. The persistent elevation of limbic HVA in nicotine-infused rats is in
agreement with studies showing that chronic exposure to nicotine elevates steady-
state DA output in the rat NAcc (Carboni et al., 2000) and DA tissue levels in the
caudate of smokers (Court et al., 1998). The ability of acute nicotine injections to
induce a further elevation of limbic, but not striatal, HVA on the 7 th day of
nicotine infusion suggests that a subpopolation of nAChRs controlling
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mesolimbic DA neurons is resistant to desensitisation. Indeed, the existence of
nAChRs resistant to desensitisation has been confirmed by several studies,
suggesting that receptors containing the 3 subunit are involved (Grady et al.,
1994; Olale et al., 1997; Wang et al., 1998).
According to Study III, nicotine’s effects on nigrostriatal DA system are more
prone to desensitisation/inactivation than its effect on mesolimbic DA system.
Results obtained here by measuring post mortem tissue concentrations of DOPAC
and HVA are partly in contrast with microdialysis data indicating that the
mesolimbic DA system is more sensitive to desensitisation than the nigrostriatal
system (Benwell and Balfour 1997; Balfour et al., 1998). A hypothetical
explanation to this discrepancy is that results obtained using in vivo microdialysis
and measurement of post mortem tissue concentrations reflect different aspects of
DA metabolism. In vivo microdialysis measures DA overflow to the extracellular
space, outside the synaptic cleft, which requires increased burst firing of midbrain
DA neurons before statistically significant increases can be detected. Post
mortem tissue concentrations of DA metabolites are probably better indicators of
intracellular DA synthesis and metabolism (Zetterström et al., 1988), and thus
increased metabolite concentrations may also reflect increased single spike firing
of DA neurons (DJK Balfour, personal communication).
Evidence exists that nicotine-induced DA release activates the expression of
immediate early genes in terminal areas of brain dopaminergic neurons via
stimulation of D
1
 and co-stimulation of NMDA receptors (Kiba and Jayaraman
1994; Nisell et al., 1997b). Therefore, the postsynaptic effects of chronic nicotine
infusion and its withdrawal in dopaminergic target areas (CeA, Cg, dorsomedial
CPu and the core of NAcc) were estimated by mapping the expression of the
protein product Fos of the immediate-early gene c-fos. Acute delivery of nicotine
elevated Fos-like immunostaining (Fos IS) in all four regions studied. In a similar
way to the effects of acute nicotine on striatal DA metabolism, attenuation of Fos
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IS was found on the 7
th
 day of chronic nicotine infusion in the areas related to the
nigrostriatal DA system, namely in the dorsomedial CPu and the core of NAcc. In
contrast, acute nicotine-induced Fos IS was not attenuated in the Cg and CeA,
which are more closely connected to the mesolimbic and mesocortical DA
systems (Loughlin and Fallon 1983; Kilts et al., 1988; Zilles and Wree 1995).
Thus, acute nicotine-induced Fos IS seems to correlate with increases of DA
metabolism in the dopaminergic terminal regions, and undergoes a similar degree
of desensitisation during chronic nicotine infusion.
Induction of nicotine withdrawal did not alter Fos IS by itself, but 24 h after the
nicotine-releasing minipumps were removed, acute nicotine induced Fos IS less
readily compared to saline-infused controls, especially in the core of NAcc. The
attenuated response might reflect persistent inactivation of Fos, similar to
nicotine’s effects on DA metabolites. However, the results from the 24 h
withdrawal experiments are somewhat inconsistent, since the acute nicotine-
induced Fos response was smaller in the Cg and NAcc of nicotine-withdrawn rats
than on the 7
th
 day of chronic infusion than in corresponding controls. Stress
induced by minipump removal is a likely contributing factor, as well as several
other unspecific factors known to confound interpretation of IEG mapping
studies (Chaudhuri 1997). More consistent is the finding that after 72 h
withdrawal, acute administration of nicotine elevated Fos IS to a similar degree in
withdrawn rats and in rats with no previous exposure to nicotine. To conclude,
Fos IS seems to be a good indicator of acute changes in brain function with a
time course of hours, but not of chronic alterations over prolonged time periods.
Changes in the expression of other, more stable IEG protein products, e.g. FosB
and chronic Fras, might better reflect chronic effects of drug treatment, as they
have been shown to accumulate in the brain during repetitive exposure to various
drugs of abuse (Hope et al., 1994; Nestler et al., 1999; Nestler 2001).
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6.9. Effects of nAChR antagonists on nicotine-induced Fos protein expression
(IV)
The aim of Study IV was to characterise the different nAChR subtypes involved
in nicotine-induced Fos IS. In accordance with earlier studies, we found that
acute nicotine administration significantly increased Fos IS in ten out of the
eleven regions investigated, excluding the mPFC (Ren and Sagar 1992; Matta et
al., 1993; Pang et al., 1993; Kiba and Jayaraman 1994; Salminen et al., 1996;
Panagis et al., 1996; Nisell et al., 1997b; Schilström et al., 2000; but see however
Mathieu-Kia et al., 1998). In Par, NAcc, CPu, IPN, PVN, SON, MT and SuG,
one or more of the three nAChR antagonists caused a significant decrease of
nicotine-induced Fos IS. Furthermore, the present study demonstrates that not
only does nicotine induce Fos in several areas, but, additionally, the nAChR
antagonists alone significantly increased Fos IS in Cg, Par, CPu, CeA, IPN, PVN,
SON, and SuG. The efficacy of nAChR antagonists in inducing Fos IS as well as
in blocking nicotine’s effects on Fos IS varied noticeably with respect to region
and antagonist. In some regions (Par, NAcc, IPN, PVN, SON, MT and SuG) the
antagonist-induced reductions of nicotine-induced Fos IS were clear-cut, whereas
in other regions (Cg, CPu and CeA) no or equivocal antagonism was obtained.
The findings that nAChR antagonists reduce and in some cases even fully inhibit
the effects of nicotine on Fos IS suggest that nAChRs mediate these effects of
nicotine. There were differences in the effects of the three antagonists studied,
suggesting that more than one subtype of nAChRs are involved in the Fos IS
induced by nicotine. Due to the lack of more selective antagonists it is not
possible to differentiate between receptor subtypes in a more conclusive manner.
DHE at the larger dose tested reduced the Fos response to nicotine in roughly
the same regions as mecamylamine. These findings suggest that in most brain
areas the Fos response to nicotine is mediated by DHE-sensitive nAChRs such
as 42. However, there were clear differences in the degree to which these two
antagonists inhibited the nicotine-induced Fos IS suggesting that DHE-
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insensitive subtypes are also involved e.g. in the IPN and MT. As described
above, MLA only reduced nicotine-induced Fos IS in the SON and MT
suggesting that in these areas 7 nAChRs are also involved in the Fos response to
nicotine.
A probable explanation to the effects of the antagonists in elevating Fos IS is that
systemic nAChR blockade alters brain IEG expression by inhibiting transmitter
release and interrupting polysynaptic feedback pathways. Alternatively, the
present findings that nAChR antagonists are able to reproduce some of nicotine's
effects at the level of immediate early genes, suggests that some of nicotine's
effects traditionally attributed to receptor activation may, instead, be caused by
desensitisation of the receptors. The latter hypothesis gains support from
electrophysiological studies in which nicotine, mecamylamine, DHE and MLA
all enhanced excitatory synaptic responses in rat hippocampal slices (Chiodini et
al., 1999).
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7. CONCLUSIONS
Nicotine’s effects on DA release depend on ambient temperature in the caudate-
putamen, but not in the nucleus accumbens. Thus, it seems that the functioning of
nigrostriatal, but not mesolimbic DA neurons is altered at elevated ambient
temperature (30-33
C vs. 20-23
C).
Studies with nicotinic acetylcholine receptor (nAChR) antagonists indicate that
the enhancement of nicotine-induced DA release in the caudate-putamen at the
higher temperature is mediated by nAChRs, and that different nAChR
subpopulations probably mediate nicotine’s effects on DA release and
metabolism.
There are differences in the desensitisation of nAChRs controlling dopaminergic
functions in the brain in response to nicotine or epibatidine. Within the
mesolimbic system, epibatidine’s effects are more prone to desensitisation than
nicotine’s effects. In contrast, within the nigrostriatal system, epibatidine’s
effects also persisted at higher doses, which indicates that desensitisation did not
occur.
During the constant presence of nicotine, the majority of nAChRs controlling
brain dopamine functions are persistently inactivated. However, a subpopulation
of nAChRs was found to be resistant to desensitisation. Furthermore, the changes
in dopaminergic function were parallel to changes in Fos protein expression in
postsynaptic cells.
The nicotine-induced increases of Fos protein expression are mediated in most
brain areas by DHE-sensitive nAChRs such as 42. However, DHE-
insensitive but mecamylamine-sensitive subtypes, as well as MLA-sensitive
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subtypes, e.g. 7-containing nAChRs, may also be involved in some of the brain
regions studied.
Systemic nAChR blockade most probably alters brain Fos expression by
inhibiting transmitter release and interrupting polysynaptic feedback pathways.
Alternatively, the present findings that nAChR antagonists are able to reproduce
some of nicotine's effects at the level of immediate early genes, suggests that
some of nicotine's effects traditionally attributed to receptor activation may in
fact be caused by desensitisation of nAChRs.
In summary, many different nAChR subtypes seem to regulate the functioning of
brain mesolimbic and nigrostriatal DA neurons. The observed differences in
agonist-induced nAChR desensitisation may prove useful in the search for new
drugs for the treatment of various diseases that involve nAChRs, e.g. Alzheimer’s
and Parkinson’s diseases, pain and schizophrenia. This may include epibatidine
analogs that desensitise mesolimbic nAChRs at low doses that might have low
abuse potential. To conclude, it seems that certain nAChRs are resistant to
inactivation even during chronic nicotine infusion, and thus may provide an
important target for the treatment of nicotine addiction and dependence.
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